Clinical Trials

Aggregated clinical trials referenced across 575 hypotheses — linked to ClinicalTrials.gov

841
Unique Trials
362
Completed
193
Recruiting
575
Hypotheses
289,899
Total Enrolled

Phase Distribution

N/A
300
Phase II
209
Phase I
130
Unknown
84
Phase III
55
Phase IV
26
Early Phase I
15
Observational
9
Phase I/II
8
Phase II/III
3
Unknown (Observational)
1
PHASE2/PHASE3
1

Status Breakdown

Completed (362)Recruiting (193)Unknown (123)Active (48)Not Yet Recruiting (45)Terminated (41)Withdrawn (13)Enrolling (9)Planning (2)Suspended (2)APPROVED_FOR_MARKETING (1)Halted (1)Available (1)
Filter by Phase
Filter by Status
Showing 200 of 841 trials (sorted by hypothesis connections)
RAPA-501 Therapy for ALS
NCT04220190 Phase II Recruiting
Rapa Therapeutics LLC 41 enrolled 2025-01-02 → 2026-07-01
RAPA-501-ALS is a phase 2/3 expansion cohort study of RAPA-501 autologous hybrid TREG/Th2 cells in patients living with amyotrophic lateral sclerosis (pwALS).
Amyotrophic Lateral SclerosisRAPA-501 Autologous T stem cells
109
hypotheses
Axonal RNA Transport ReconstitutionEndothelial Glycocalyx Regeneration via Syndecan-1 UpregulatExtracellular Matrix Stiffness Modulation+106 more
MAD Phase I Study to Investigate Contraloid Acetate
NCT03955380 Phase I Completed
Prof. Dr. Dieter Willbold 24 enrolled 2018-12-12 → 2019-04-03
This is a single-center multiple-ascending-dose clinical trial assessing the safety and tolerability of oral dosing of Contraloid acetate in healthy volunteers. The study drug Contraloid (alias RD2, a
Alzheimer DementiaAlzheimer DiseaseContraloid
109
hypotheses
Axonal RNA Transport ReconstitutionEndothelial Glycocalyx Regeneration via Syndecan-1 UpregulatExtracellular Matrix Stiffness Modulation+106 more
Cerebrovascular Reactivity and Oxygen Metabolism as Markers of Neurodegeneration After Traumatic Brain Injury
NCT04820881 N/A Unknown
Washington D.C. Veterans Affairs Medical Center 60 enrolled 2021-10-01 → 2024-09
This grant award entitled, "Cerebrovascular Reactivity and Oxygen Metabolism as Markers for Neurodegeneration after Traumatic Brain Injury" (hereafter, "Neurovascular Study"), aims to determine if neu
Neurodegenerative Diseases
109
hypotheses
Axonal RNA Transport ReconstitutionEndothelial Glycocalyx Regeneration via Syndecan-1 UpregulatExtracellular Matrix Stiffness Modulation+106 more
Stereotactic Intracerebral Injection of Allogenic IPSC-DAPs in Patients With Parkinson's Disease
NCT07212088 Phase I Not Yet Recruiting
iCamuno Biotherapeutics Ltd. 12 enrolled 2026-02-28 → 2027-12-15
Parkinson's disease is a progressive neurodegenerative disorder characterized by high morbidity due to the limited regenerative capacity of dopaminergic neurons in the brain. Current drug treatments p
Parkinson DiseaseALC01 therapy
109
hypotheses
Axonal RNA Transport ReconstitutionEndothelial Glycocalyx Regeneration via Syndecan-1 UpregulatExtracellular Matrix Stiffness Modulation+106 more
MRI Biomarkers in ALS
NCT02405182 N/A Completed
University of Alberta 145 enrolled 2014-09 → 2019-03
Amyotrophic lateral sclerosis (ALS) is a disabling and rapidly progressive neurodegenerative disorder. There is no treatment that significantly slows progression. Increasing age is an important risk f
Amyotrophic Lateral SclerosisALSMotor Neuron DiseasesMagnetic Resonance Imaging
109
hypotheses
Axonal RNA Transport ReconstitutionEndothelial Glycocalyx Regeneration via Syndecan-1 UpregulatExtracellular Matrix Stiffness Modulation+106 more
Activity of Cerebral Networks, Amyloid and Microglia in Aging and Alzheimer's Disease
NCT06224920 Unknown Completed
Ludwig-Maximilians - University of Munich 140 enrolled 2017-01-01 → 2024-01-01
The temporal sequence of microglial activation, changes in functional and structural connectivity and the progression of neurocognitive deficits has not been conclusively clarified. To date, there hav
Alzheimer DiseaseCorticobasal Syndromemagnetic resonance imagingelectroencephalographyblood and CSF biomarker
63
hypotheses
TREM2-Dependent Senescent Microglia Disrupt Astrocyte CommunTREM2-Mediated Cholesterol Dysregulation in Microglial SenesTREM2-Mediated Microglial Dysfunction Disrupts Oligodendrocy+60 more
The Signature of Alzheimer's Disease in Subjective Cognitive Decline
NCT07402161 Unknown Recruiting
IRCCS Policlinico S. Donato 250 enrolled 2025-10-01 → 2027-10-01
This study focuses on improving early detection of Alzheimer's disease (AD) in patients with subjective cognitive decline (SCD), a preclinical stage of cognitive impairment, in the context of emerging
Subjective Cognitive Decline (SCD)Subjective Cognitive Complaints (SCCs)Subjective Cognitive Impairment
44
hypotheses
TREM2-Dependent Senescent Microglia Disrupt Astrocyte CommunTREM2-Mediated Cholesterol Dysregulation in Microglial SenesTREM2-Mediated Microglial Dysfunction Disrupts Oligodendrocy+41 more
Neurofilament Light Chain And Voice Acoustic Analyses In Dementia Diagnosis
NCT06339190 N/A Recruiting
Monash University 1,000 enrolled 2021-08-01 → 2025-12
This cohort study aims to determine if a blood test can aid with diagnosing dementia in anyone presenting with cognitive complaints to a single healthcare network. The investigators will measure level
Neurodegenerative DiseasesDementiaVenepuncture
43
hypotheses
Axonal RNA Transport ReconstitutionTREM2-Dependent Senescent Microglia Disrupt Astrocyte CommunTREM2-Mediated Cholesterol Dysregulation in Microglial Senes+40 more
Leucettinib-21 First-in-Human Phase 1 in Healthy Volunteers and Subjects With Down Syndrome and Alzheimer's Disease
NCT06206824 Phase I Recruiting
Perha Pharmaceuticals
Healthy VolunteersDown SyndromeAlzheimer's DiseaseLeucettinib-21
43
hypotheses
Alpha-Beta Oscillation Coupling Enhances lncRNA-9969-MediateClosed-loop tACS targeting EC-II SST interneurons to block tTheta-Gamma Coupling Modulates lncRNA-9969-Mediated Mitochon+40 more
Cognitive-motor Training in Community-dwelling Older People With Mild Cognitive Impairment
NCT07241598 N/A Not Yet Recruiting
Mahidol University 70 enrolled 2025-12-01 → 2027-12-01
As the global population ages, the prevalence of mild cognitive impairment (MCI) among older adults, which ranges from 5% to 40%, is expected to rise. MCI significantly increases the risk of developin
Mild Cognitive Impairment (MCI)Smart±step cognitive-motor training
40
hypotheses
Closed-loop tACS targeting EC-II SST interneurons to block tClosed-loop transcranial focused ultrasound targeting entorhClosed-loop tACS targeting EC-II somatostatin interneurons t+37 more
The Effects of Exercise on Synaptic Plasticity in Individuals With Mild Cognitive Impairment and in Healthy Aging.
NCT05663918 N/A Unknown
McMaster University 36 enrolled 2023-02-13 → 2025-01-01
The research is focused on ameliorating cognitive decline in aging and in individuals diagnosed with Mild Cognitive Impairment (MCI). In the proposed research, we ask whether synaptic plasticity is mo
Mild Cognitive ImpairmentSelf- determined Intensity Interval Trai
40
hypotheses
Closed-loop tACS targeting EC-II SST interneurons to block tClosed-loop transcranial focused ultrasound targeting entorhClosed-loop tACS targeting EC-II somatostatin interneurons t+37 more
Clinical, Molecular and Electrophysiological Profiling of Parkinson's Disease: the Role of Non-pharmacological Therapies
NCT05807581 N/A Unknown
Fondazione Policlinico Universitario Agostino Geme 400 enrolled 2023-06-09 → 2025-05-30
In Parkinson's disease (PD), direct evidence linking inflammation to the harmful activities of alpha-synuclein (a-syn) aggregates, the disease onset, and its progression is still lacking. This transla
Parkinson Diseasephysical activityiTBS
29
hypotheses
TREM2-Dependent Senescent Microglia Disrupt Astrocyte CommunTREM2-Mediated Cholesterol Dysregulation in Microglial SenesTREM2-Mediated Astrocyte-Microglia Cross-Talk in Neurodegene+26 more
A Noval Tau Tracer in Young Onset Dementia
NCT04248270 Phase I Unknown
Chang Gung Memorial Hospital 100 enrolled 2020-02-20 → 2023-08-17
Dementia is a clinical syndrome which characterized by progressive cognitive impairment, behavior disturbance and dysfunction of daily activity. In aging population, Alzheimer's dementia (AD) is the m
Alzheimer's DiseaseVascular DementiaDementia18F-PM-PBB3
28
hypotheses
Metabolic Reprogramming via Coordinated Multi-Gene CRISPR CiProgrammable Neuronal Circuit Repair via Epigenetic CRISPR...+25 more
An Innovative Method in SAliva Samples for the Early Differential Diagnosis of High-impact NeuroDegenerative Diseases Th
NCT06875739 Unknown Enrolling
Fondazione Don Carlo Gnocchi Onlus 310 enrolled 2025-02-14 → 2026-10-01
The aim of the study is to validate a salivary test that allows for rapid and accurate objective diagnosis in the context of neurodegenerative diseases, a complex of diseases that includes Alzheimer's
Neurodegenerative DisordersParkinson DiseaseAlzheimer Disease
27
hypotheses
Metabolic Reprogramming via Coordinated Multi-Gene CRISPR CiProgrammable Neuronal Circuit Repair via Epigenetic CRISPR...+24 more
Physical Activity in Patients With Parkinson's Disease: a "Disease Modifying" Intervention?
NCT05815524 N/A Terminated
Fondazione Policlinico Universitario Agostino Geme 30 enrolled 2022-05-02 → 2024-12-31
Parkinson's disease (PD) is a neurodegenerative disease characterized by bradykinesia, rigors, and tremor at rest. Distinctive neuropathological signs include progressive loss of dopaminergic neurons
Parkinson DiseasePhysical activity training
27
hypotheses
TREM2-Dependent Senescent Microglia Disrupt Astrocyte CommunTREM2-Mediated Cholesterol Dysregulation in Microglial SenesTREM2-Mediated Astrocyte-Microglia Cross-Talk in Neurodegene+24 more
Simufilam (PTI-125), 100 mg, for Mild-to-moderate Alzheimer's Disease Patients
NCT04388254 Phase II Completed
Cassava Sciences, Inc.
Alzheimer DiseaseSimufilam 100 mg oral tabletPlacebo
22
hypotheses
TREM2-Mediated Microglial Dysfunction Disrupts OligodendrocyMicroglial TREM2-SYK Pathway EnhancementTREM2-Mediated Microglial Checkpoint Therapy+19 more
Neuroinflammation and Neurodegeneration in HIV-positive Subjects Switched and Initially Treated With INSTI
NCT04887675 N/A Unknown
University of Novi Sad 120 enrolled 2021-05-01 → 2022-06-01
Since the HIV changed its course to the chronic disease, high incidence of metabolic syndrome both in HIV positive and negative subjects has become an issue. Given the successful peripheral suppressio
HIV I InfectionHIV Associated LipodystrophyMetabolic SyndromeMRI
20
hypotheses
Metabolic Reprogramming via Coordinated Multi-Gene CRISPR CiProgrammable Neuronal Circuit Repair via Epigenetic CRISPR...+17 more
Natural History of Glycosphingolipid Storage Disorders and Glycoprotein Disorders
NCT00029965 Unknown Recruiting
National Human Genome Research Institute (NHGRI) 200 enrolled Started 2002-02-06
Study description: This is a natural history study that will evaluate any patient with enzyme or DNA confirmed GM1 or GM2 gangliosidosis, sialidosis or galactosialidosis. Patients may be evaluated ev
Neurological RegressionMyoclonusCherry Red Spot
20
hypotheses
Metabolic Reprogramming via Coordinated Multi-Gene CRISPR CiProgrammable Neuronal Circuit Repair via Epigenetic CRISPR...+17 more
Retinal and Cognitive Dysfunction in Type 2 Diabetes
NCT04281186 Unknown Completed
Hospital Universitari Vall d'Hebron Research Insti 510 enrolled 2020-11-16 → 2024-12-12
The retina shares similar embryologic origin, anatomical features and physiological properties with the brain and hence offers a unique and accessible "window" to study the correlates and consequences
Retinal FunctionCognitive DysfunctionMicroperimetry
20
hypotheses
Metabolic Reprogramming via Coordinated Multi-Gene CRISPR CiProgrammable Neuronal Circuit Repair via Epigenetic CRISPR...+17 more
Randomized I/II Phase Study of ALZT-OP1 Combination Therapy in Alzheimer's Disease and Normal Healthy Volunteers
NCT04570644 Phase I Completed
AZTherapies, Inc.
Healthy VolunteersAlzheimer DiseaseALZT-OP1 (cromolyn and ibuprofen) ALZT-O
17
hypotheses
TREM2-Mediated Microglial Dysfunction Disrupts OligodendrocyTREM2-Mediated Microglial Checkpoint TherapyTREM2-Mediated Microglial Metabolic Reprogramming Accelerate+14 more
DORA and LP in Alzheimer's Disease Biomarkers
NCT06274528 Phase II Recruiting
Washington University School of Medicine
Alzheimer DiseaseLemborexant 10 mgLemborexant 20mgPlacebo
15
hypotheses
TREM2-Mediated Microglial Dysfunction Disrupts OligodendrocyNight-phase orexin receptor antagonism rescues AD by restoriTREM2-Mediated Microglial Checkpoint Therapy+12 more
Search for Biomarkers of Neurodegenerative Diseases in Idiopathic REM Sleep Behavior Disorder
NCT04048603 N/A Unknown
Chinese University of Hong Kong 182 enrolled 2019-05-15 → 2022-03-31
This study is a prospective study with a mean of 7-year follow-up interval, aims to monitor the progression of α-synucleinopathy neurodegeneration by the evolution of prodromal markers and development
REM Sleep Behavior DisorderNeurodegeneration
13
hypotheses
Microglial TREM2-SYK Pathway EnhancementTREM2 Agonism to Reprogram Infiltrated Monocytes Toward NeurStathmin-2 Splice Switching to Prevent Axonal Degeneration A+10 more
Efficacy of Dorzolamide as an Adjuvant After Focal Photocoagulation in Clinically Significant Macular Edema
NCT02227745 N/A Unknown
Hospital Juarez de Mexico 60 enrolled 2014-01 → 2015-03
Photocoagulation is the standard treatment in the focal EMCS, disrupts vascular leakage and allows the pigment epithelium remove the intraretinal fluid is effective in reducing the incidence of visual
Diabetic RetinopathyDiabetic Macular EdemaDorzolamide hydrochloride (2%)Placebo Sodium hyaluronate 4mg
13
hypotheses
Microglial TREM2-SYK Pathway EnhancementTREM2 Agonism to Reprogram Infiltrated Monocytes Toward NeurStathmin-2 Splice Switching to Prevent Axonal Degeneration A+10 more
Evaluation of the Frequency and Severity of Sleep Abnormalities in Patients With Parkinson's Disease
NCT04387812 N/A Unknown
Tel-Aviv Sourasky Medical Center 240 enrolled 2020-06-01 → 2023-12-31
Sleep disturbances are one of the most common non-motor symptoms in PD, with an estimated prevalence as high as 40-90%. Sleep disturbances (particularly sleep duration, sleep fragmentation, Rapid Eye
Parkinson DiseaseGBA Gene MutationLeucine-rich Repeat Kinase 2 (LRRK2) GenXtrodes home PSG system
13
hypotheses
Microglial TREM2-SYK Pathway EnhancementTREM2 Agonism to Reprogram Infiltrated Monocytes Toward NeurStathmin-2 Splice Switching to Prevent Axonal Degeneration A+10 more
Ambroxol in Disease Modification in Parkinson Disease
NCT02941822 Phase II Completed
University College, London 23 enrolled 2016-12 → 2018-04
This study will evaluate the safety, tolerability and pharmacodynamics of ambroxol in participants with Parkinson Disease. Participants will administer ambroxol at five dose levels and will undergo cl
Parkinson DiseaseAmbroxol
13
hypotheses
Microglial TREM2-SYK Pathway EnhancementTREM2 Agonism to Reprogram Infiltrated Monocytes Toward NeurStathmin-2 Splice Switching to Prevent Axonal Degeneration A+10 more
Development of a Novel 18F-DTBZ PET Imaging as a Biomarker to Monitor Neurodegeneration of PARK6 and PARK8 Parkinsonism
NCT01759888 Phase II Completed
Chang Gung Memorial Hospital 49 enrolled 2011-08 → 2014-12
The primary objective of this protocol is to access the utility of 18F-DTBZ PET imaging as an in vivo biomarker to monitor neurodegeneration of both PD mouse models and PD patients. Secondary, the inv
Parkinson's Disease18F-DTBZ
13
hypotheses
Microglial TREM2-SYK Pathway EnhancementTREM2 Agonism to Reprogram Infiltrated Monocytes Toward NeurStathmin-2 Splice Switching to Prevent Axonal Degeneration A+10 more
The Analysis of Gene Variants Related to POCD in Elderly Patients
NCT05419596 N/A Unknown
Istanbul University 126 enrolled 2022-07-01 → 2023-07-01
The pathophysiology of postoperative cognitive dysfunction (POCD) following surgery may be related to Alzheimer's disease. Different studies show that; low levels of glial cell line-derived growth fac
Cognitive DysfunctionUrologic Surgery
12
hypotheses
Microglial TREM2-SYK Pathway EnhancementTREM2-Mediated Microglial Checkpoint TherapyTREM2 Agonism to Reprogram Infiltrated Monocytes Toward Neur+9 more
Ferrochelating Treatment in Patients Affected by Neurodegeneration With Brain Iron Accumulation (NBIA)
NCT00907283 Phase II Unknown
Ente Ospedaliero Ospedali Galliera 20 enrolled 2008-11 → 2024-12
This trial is a multicenter, unblinded, single-arm pilot study, lasting one year (plus one year extension Amendment n.3 25 August 2009, plus two years follow-up Amendment n.7) , to evaluate the effica
Neurodegenerative DiseaseIron OverloadDeferiprone
11
hypotheses
TFEB-PGC1α Mitochondrial-Lysosomal DecouplingSenescent Cell ASM-Complement Cascade InterventionAstrocyte-Mediated Neuronal Epigenetic Rescue+8 more
N-Acetylcysteine for Neurodegeneration in PD
NCT03514875 Phase II Completed
Parkinson DiseaseNeurodegenerationN-Acetylcysteine
10
hypotheses
ACSL4-Ferroptotic Priming in Stressed Oligodendrocytes DriveLPCAT3-Mediated Lands Cycle Amplification of Ferroptotic VulACSL4-Driven Ferroptotic Priming in Disease-Associated Oligo+7 more
A Study of an Investigational Drug to See How it Affects the People With Parkinson's Disease Complicated by Motor Fluctu
NCT03391882 Phase III Completed
Sumitomo Pharma America, Inc. 113 enrolled 2018-12-19 → 2021-08-11
A study of an investigational drug to see how it affects the people with Parkinson's Disease complicated by motor fluctuations ("OFF" Episodes) compared to an approved drug used to treat people with P
Motor OFF Episodes Associated With ParkiAPL-130277subcutaneous apomorphine
10
hypotheses
GluN2B-Mediated Microglial Activation and Tau PropagationGluN2B-Regulated Microglial Phagocytosis of Tau Aggregates vKetone-Primed Thalamocortical Enhancement of Glymphatic Tau +7 more
Protective Anesthesiological Management Procedure Imposes Control on Respiratory Comlications
NCT06282003 N/A Unknown
Masa Kontic 53 enrolled 2023-10-10 → 2024-06-30
Anesthetic effects, surgery, and invasive mechanical intubation can impair respiratory function during general anesthesia. The risk factors for postoperative pulmonary complications (PPCs) include the
Well-Being, PsychologicalThe procedure of protective lung ventila
10
hypotheses
GluN2B-Mediated Microglial Activation and Tau PropagationGluN2B-Regulated Microglial Phagocytosis of Tau Aggregates vKetone-Primed Thalamocortical Enhancement of Glymphatic Tau +7 more
Long-Term Safety of PRC-063 in Adolescents and Adults With ADHD
NCT02168127 Phase III Completed
Rhodes Pharmaceuticals, L.P. 360 enrolled 2014-05 → 2015-05
The purpose of this six month, open-label study is to evaluate the long-term safety and efficacy of PRC-063 in adults and adolescents with ADHD.
ADHDDrug: PRC-063PRC-063
10
hypotheses
GluN2B-Mediated Microglial Activation and Tau PropagationGluN2B-Regulated Microglial Phagocytosis of Tau Aggregates vKetone-Primed Thalamocortical Enhancement of Glymphatic Tau +7 more
5-Aminolevulinic Acid (5-ALA) to Enhance Visualization of Malignant Tumor
NCT02632370 N/A Completed
Constantinos Hadjipanayis 69 enrolled 2016-05 → 2018-12-31
In support of the US marketing application for 5-ALA, this single arm trial is being conducted to establish the efficacy and safety of Gliolan® (5-ALA) in patients with newly diagnosed or recurrent ma
Malignant GliomasGliolan®Fluorescence-Guided Surgery
10
hypotheses
GluN2B-Mediated Microglial Activation and Tau PropagationGluN2B-Regulated Microglial Phagocytosis of Tau Aggregates vKetone-Primed Thalamocortical Enhancement of Glymphatic Tau +7 more
Magnetic Resonance Imaging of Brain Development in Autism
NCT00449566 N/A Unknown
UMC Utrecht 300 enrolled Started 2006-01
The purpose of this study is to investigate brain development in autism by longitudinally assessing children with autism, as well as typically developing controls, using advanced MR techniques. We wil
Autism
10
hypotheses
GluN2B-Mediated Microglial Activation and Tau PropagationGluN2B-Regulated Microglial Phagocytosis of Tau Aggregates vKetone-Primed Thalamocortical Enhancement of Glymphatic Tau +7 more
PRedicting the EVolution of SubjectIvE Cognitive Decline to Alzheimer's Disease With Machine Learning
NCT05569083 N/A Unknown
Azienda Ospedaliero-Universitaria Careggi 350 enrolled 2020-10-01 → 2023-09-30
Alzheimer's disease (AD) has a presymptomatic course which can last from several years to decades. Identification of subjects at an early stage is crucial for therapeutic intervention and possible pre
Cognitive DeclineMild Cognitive ImpairmentAlzheimer DiseaseGenetic analysis of APOE and BDNF genes.EEG recordingCSF collection and AD biomarker measurem
10
hypotheses
Targeted APOE4-to-APOE3 Base Editing TherapyCompetitive APOE4 Domain Stabilization PeptidesAPOE4 Allosteric Rescue via Small Molecule Chaperones+7 more
Association of VAgus Nerve Stimulation and Treadmill Training for GAit Rehabilitation in DE Novo Parkinson's Disease
NCT07337226 N/A Not Yet Recruiting
Fondazione Policlinico Universitario Campus Bio-Me 60 enrolled 2026-01 → 2027-10
The goal of this clinical trial is to learn if transcutaneous auricular vagus nerve stimulation (taVNS) can improve gait and brain function in people with diagnosis of idiopathic Parkinson's disease (
Idiopathic Parkinson's Disease (PD)Transcutaneous Auricular Vagus Nerve StiSham Transcutaneous Auricular Vagus NervConventional Physical Therapy (cPT)
10
hypotheses
TFEB-PGC1α Mitochondrial-Lysosomal DecouplingSenescent Cell ASM-Complement Cascade InterventionAstrocyte-Mediated Neuronal Epigenetic Rescue+7 more
The NO-ALS Study: A Trial of Nicotinamide/Pterostilbene Supplement in ALS.
NCT04562831 N/A Active
Haukeland University Hospital 380 enrolled 2020-10-07 → 2026-10-31
Amyotrophic lateral sclerosis (ALS) is a serious rapidly progressive disease of the nervous system. The average survival from the time of diagnosis is 3 years. Apart from Riluzole, there is no effecti
Amyotrophic Lateral SclerosisEH301 (Nicotinamide Riboside/Pterostilbe
10
hypotheses
TFEB-PGC1α Mitochondrial-Lysosomal DecouplingSenescent Cell ASM-Complement Cascade InterventionAstrocyte-Mediated Neuronal Epigenetic Rescue+7 more
Effect of the Vojta Therapy in Patients Multiple Sclerosis
NCT05558683 N/A Unknown
Aymara Abreu Corrales 25 enrolled 2022-12-01 → 2023-06-01
Multiple sclerosis is the most common disabling neurological disease in young adults. Inflammation, demyelination, neurodegeneration, gliosis and repair processes are involved in its process, which ar
Multiple SclerosisRandomized clinical trial.
10
hypotheses
TFEB-PGC1α Mitochondrial-Lysosomal DecouplingSenescent Cell ASM-Complement Cascade InterventionAstrocyte-Mediated Neuronal Epigenetic Rescue+7 more
The Effect of RNS60 on ALS Biomarkers
NCT03456882 Phase II Completed
Mario Negri Institute for Pharmacological Research 147 enrolled 2017-05-30 → 2020-11-23
Amyotrophic Lateral Sclerosis (ALS) is a rare lethal neurodegenerative disease involving inflammation. Riluzole, the only drug for ALS, improves median survival by 3 months. This prompts new treatment
Amyotrophic Lateral SclerosisRNS60
10
hypotheses
TFEB-PGC1α Mitochondrial-Lysosomal DecouplingSenescent Cell ASM-Complement Cascade InterventionAstrocyte-Mediated Neuronal Epigenetic Rescue+7 more
Deferiprone for Iron Reduction in Alzheimer's Disease
NCT03234686 Phase II Completed
Alzheimer DiseaseDeferiprone
9
hypotheses
ACSL4-Ferroptotic Priming in Stressed Oligodendrocytes DriveLPCAT3-Mediated Lands Cycle Amplification of Ferroptotic VulACSL4-Driven Ferroptotic Priming in Disease-Associated Oligo+6 more
Effect of Selenium on Mild Cognitive Impairment
NCT03533257 Phase II Completed
Mild Cognitive ImpairmentSelenomethionine
9
hypotheses
ACSL4-Ferroptotic Priming in Stressed Oligodendrocytes DriveLPCAT3-Mediated Lands Cycle Amplification of Ferroptotic VulACSL4-Driven Ferroptotic Priming in Disease-Associated Oligo+6 more
Pioglitazone in Alzheimer Disease (TOMORROW)
NCT00000145 Phase III Completed
Alzheimer DiseasePioglitazone
9
hypotheses
ACSL4-Ferroptotic Priming in Stressed Oligodendrocytes DriveLPCAT3-Mediated Lands Cycle Amplification of Ferroptotic VulACSL4-Driven Ferroptotic Priming in Disease-Associated Oligo+6 more
Vitamin E and Selenium in Preventing AD
NCT05081219 Phase II Recruiting
Alzheimer Disease PreventionVitamin ESelenium
9
hypotheses
ACSL4-Ferroptotic Priming in Stressed Oligodendrocytes DriveLPCAT3-Mediated Lands Cycle Amplification of Ferroptotic VulACSL4-Driven Ferroptotic Priming in Disease-Associated Oligo+6 more
The Effects of a Novel NMDA NR2B-Subtype Selective Antagonist, EVT 101, on Brain Function
NCT00526968 Phase I Completed
Evotec Neurosciences GmbH 19 enrolled 2007-09 → 2007-12
The purpose of this study is to investigate the neurophysiological changes following single doses of EVT 101 using fMRI during rest and during cognitive tasks in young healthy male subjects.
Human VolunteersEVT 101EVT 101placebo
9
hypotheses
GluN2B-Mediated Microglial Activation and Tau PropagationGluN2B-Regulated Microglial Phagocytosis of Tau Aggregates vKetone-Primed Thalamocortical Enhancement of Glymphatic Tau +6 more
The Dortmund Vital Study: Impact of Biological and Lifestyle Factors on Cognitive Performace and Work Ability
NCT05155397 N/A Active
Technical University of Dortmund 627 enrolled 2016-04 → 2035-12
The goal of the Dortmund Vital Study is to validate previous hypotheses and to generate and validate new hypotheses about the relationship of ageing, working conditions, genetic makeup, stress, metabo
Age-related Cognitive Decline
9
hypotheses
GluN2B-Mediated Microglial Activation and Tau PropagationGluN2B-Regulated Microglial Phagocytosis of Tau Aggregates vKetone-Primed Thalamocortical Enhancement of Glymphatic Tau +6 more
DL-3-n-butylphthalide Treatment in Patients With Mild to Moderate Alzheimer's Disease Already Receiving Donepezil
NCT02711683 N/A Completed
First Affiliated Hospital Xi'an Jiaotong Universit 92 enrolled 2016-03 → 2019-12
Alzheimer's disease (AD) is the commonest cause of dementia. There is no effective treatment to cure the disease. Cholinesterase inhibitors, such as donepezil, are widely recommended to patients with
Alzheimer's DiseaseDL-3-n-butylphthalideDonepezil
9
hypotheses
GluN2B-Mediated Microglial Activation and Tau PropagationGluN2B-Regulated Microglial Phagocytosis of Tau Aggregates vKetone-Primed Thalamocortical Enhancement of Glymphatic Tau +6 more
Neuroinflammation in FTLD
NCT06870838 N/A Active
Leiden University Medical Center 110 enrolled 2023-07-25 → 2025-08-01
The goal of this observational study is to investigate the role of neuroinflammation in frontotemporal lobar degeneration (FTLD). The main aims of this study are: 1. To elucidate the role and timing
Corticobasal Syndrome(CBS)Primary Progressive Aphasia(PPA)Progressive Supranuclear Palsy(PSP)7T MRI scanCSFBlood withdrawal
9
hypotheses
Glymphatic System-Enhanced Antibody Clearance ReversalTREM2-Mediated Microglial Dysfunction Disrupts Perivascular SASP-Driven Aquaporin-4 Dysregulation+6 more
ALA-enriched Nutrition for Prevention of Cognitive Decline in APOE4 Older Adults
NCT07392723 Phase II Recruiting
Michal Schnaider Beeri, Ph.D. 20 enrolled 2025-01-12 → 2027-04
This randomized, double-blind, placebo-controlled pilot trial will evaluate the effects of alpha-linolenic acid (ALA) supplementation on cognitive function, blood-brain barrier integrity, and brain va
Cognitive DysfunctionAlzheimer DiseaseBlood-Brain BarrierAlpha-Linolenic Acid (2.6 g/day)Placebo Control Group
9
hypotheses
Targeted APOE4-to-APOE3 Base Editing TherapyCompetitive APOE4 Domain Stabilization PeptidesAPOE4 Allosteric Rescue via Small Molecule Chaperones+6 more
An Extension Study to Evaluate the Long-Term Safety and Tolerability of JNJ-54861911 in Participants in the Early Alzhei
NCT02406027 Phase II Terminated
Janssen Research & Development, LLC
Alzheimer DiseaseJNJ-54861911, 10 mgJNJ-54861911, 25 mgPlacebo
9
hypotheses
Excitatory Neuron Synaptic Dysfunction and Mitochondrial StrGlymphatic-Cholinergic Tau Clearance CascadeSelective Tau Kinase Inhibition in Vulnerable Neuronal Subty+6 more
Efavirenz for Patients With Alzheimer's Disease
NCT03706885 Phase I Completed
Case Western Reserve University 5 enrolled 2018-05-05 → 2022-01-28
This will be a two-center, placebo controlled blinded clinical trial to evaluate the safety and tolerability of efavirenz (EFV) in 36 clinically stable subjects with mild cognitive impairment/early de
Alzheimer Disease, Early OnsetSustiva Pill
8
hypotheses
CYP46A1 Suppression for Tau-Mediated NeurodegenerationCholesterol-CRISPR Convergence Therapy for NeurodegenerationCYP46A1 Gene Therapy for Age-Related TREM2-Mediated Microgli+5 more
A Single Site, Randomized, Double-blind, Placebo Controlled Trial of NIC5-15 in Subjects With Alzheimer's Disease
NCT01928420 Phase II Completed
Humanetics Corporation 30 enrolled 2007-04 → 2014-06
The purpose of this study is to evaluate the safety and efficacy of NIC5-15 in the treatment of Alzheimer's Disease.
Alzheimer's DiseaseDementiaDrug: NIC5-15Placebo
8
hypotheses
Targeted APOE4-to-APOE3 Base Editing TherapyCompetitive APOE4 Domain Stabilization PeptidesAPOE4 Allosteric Rescue via Small Molecule Chaperones+5 more
Continuation of The Kronos Early Estrogen Prevention Study (KEEPS)
NCT03718494 Unknown Completed
Mayo Clinic
Alzheimer DementiaBrain Magnetic Resonance Imaging (MRI)F-18 Florbetapir Positron Emission TomogF-18 AV-1451 Positron Emission Tomograph
8
hypotheses
Excitatory Neuron Synaptic Dysfunction and Mitochondrial StrGlymphatic-Cholinergic Tau Clearance CascadeSelective Tau Kinase Inhibition in Vulnerable Neuronal Subty+5 more
Clinical Safety and Efficacy Evaluation of NanoLithium® NP03 in Patients With Mild-to-severe Alzheimer's Disease
NCT05423522 Phase II Completed
Medesis Pharma SA
Alzheimer's DiseaseNanoLithium® NP03Placebo
8
hypotheses
Excitatory Neuron Synaptic Dysfunction and Mitochondrial StrGlymphatic-Cholinergic Tau Clearance CascadeSelective Tau Kinase Inhibition in Vulnerable Neuronal Subty+5 more
A Study to Evaluate AB-1001 Striatal Administration in Adults With Early Manifest Huntington's Disease
NCT05541627 Phase I Active
Brainvectis, a subsidiary of Asklepios BioPharmace 5 enrolled 2022-10-12 → 2024-04-04
A Phase I/II Dose-Finding Study to Evaluate Striatal Administration of AB-1001 (previously BV-101) in Adults with Early Manifest Huntington's Disease
Huntington DiseaseAB-1001 Gene Therapy
7
hypotheses
CYP46A1 Suppression for Tau-Mediated NeurodegenerationCYP46A1 Gene Therapy for Age-Related TREM2-Mediated MicrogliCYP46A1 Small Molecule Activator Therapy+4 more
Predictive Role of sTREM in Endovascular Thrombectomy Outcomes
NCT06545591 N/A Recruiting
The Affiliated Hospital of Xuzhou Medical Universi
Soluble triggering receptor expressed on myeloid cells (sTREM), which reflects microglia activation, has been reported closely associated with neuronal injury and neuroinflammation. This study is to i
Acute Ischemic Stroke
7
hypotheses
TREM2-Mediated Microglial Dysfunction Disrupts Perivascular TREM2-Regulated Astrocytic Calcium Dynamics Control GlymphatTREM2-Mediated Microglial Dysfunction Impairs Synaptic Tau P+4 more
Allopregnanolone Regenerative Therapeutic for Mild Alzheimer's Disease
NCT04838301 Phase II Recruiting
University of Arizona 100 enrolled 2023-08-15 → 2026-11-18
A phase 2, double-blind, randomized, placebo-controlled clinical trial to evaluate the safety and efficacy of Allopregnanolone as a regenerative therapeutic for Alzheimer's disease.
Alzheimer DementiaLate Onset Alzheimer DiseaseNeurodegenerative DiseasesAllopregnanolonePlacebo
6
hypotheses
HSP90-Tau Disaggregation Complex EnhancementAPOE Isoform Expression Across Glial SubtypesExcitatory Neuron Vulnerability via SLC17A7 Downregulation+3 more
Impact of Bosutinib on Safety, Tolerability, Biomarkers and Clinical Outcomes in Dementia With Lewy Bodies
NCT03888222 Phase II Completed
Georgetown University 26 enrolled 2019-04-23 → 2021-08-27
This study evaluates the effect of Bosutinib (Bosulif,Pfizer®) in the treatment of patients with Dementia with Lewy Bodies. Half participants will receive 100 mg of Bosutinib , while the other half wi
Dementia With Lewy BodiesPlacebo Oral TabletBosutinib Oral Tablet
6
hypotheses
Microglial TREM2-SYK Pathway EnhancementTREM2 Agonism to Reprogram Infiltrated Monocytes Toward NeurH1: TREM2 Agonism to Redirect APOE4-Enhanced Microglia from +3 more
Hyperhomocysteinemia in Alzheimer's Disease
NCT05793372 Unknown Unknown
Central Hospital, Nancy, France
Alzheimer DiseaseHomocystinemiaRetrospective study of clinical features
6
hypotheses
TREM2-Mediated Microglial Metabolic Reprogramming AccelerateTREM2-Mediated Microglial Dysfunction Drives Tau-Induced BloDisease-Associated Microglia Metabolic Reprogramming+3 more
Understanding Cerebral Blood Flow Dynamics for Alzheimer's Disease Prevention Through Exercise
NCT06584656 N/A Completed
Universidad de Granada
Healthy AgingCognitive Function 1, SocialCerebrovascular CirculationAerobic exercise conditionResistance exercise condition
6
hypotheses
A tau PTM barcode gates trans-synaptic templatingTau/MAP6 ratio as a master switch for microtubule dynamics pRepeat-domain exposure defines seed-competent tau conformers+3 more
Intermittent Calorie Restriction, Insulin Resistance, and Biomarkers of Brain Function
NCT02460783 N/A Completed
National Institute on Aging (NIA) 129 enrolled 2015-06-22 → 2022-01-14
Alzheimer's DiseaseObesityDiabetes MellitusBoost (R) 5-2 dietHealthy Living Diet
6
hypotheses
Parvalbumin Interneuron Vulnerability Links Lactate TransporGlycine-Rich Domain Competitive InhibitionCross-Seeding Prevention Strategy+3 more
A Study of RO5313534 as Add-on to Donepezil Treatment in Patients With Mild to Moderate Alzheimer's Disease
NCT00884507 Phase II Completed
Hoffmann-La Roche 389 enrolled 2009-05 → 2010-11
This 4 arm study will assess the efficacy and safety of RO5313534 (MEM3454) versus placebo added to donepezil, in patients with mild to moderate Alzheimer's disease. Following a screening period, pati
Alzheimer's DiseasePlaceboRO5313534RO5313534
5
hypotheses
HSP90-Tau Disaggregation Complex EnhancementAPOE Isoform Expression Across Glial SubtypesGFAP-Positive Reactive Astrocyte Subtype Delineation+2 more
Effects of a Cognitive-Engaging Strength Training Program on Health, Physical Condition, and Quality of Life in People W
NCT07022431 N/A Not Yet Recruiting
University of Seville 34 enrolled 2025-10 → 2025-10
The primary objective of this project is to examine the impact of a strength training program with high cognitive demands on cognitive function, motor skills, physical fitness, and quality of life in
Alzheimer DiseaseInterval strength training
5
hypotheses
HSP90-Tau Disaggregation Complex EnhancementAPOE Isoform Expression Across Glial SubtypesGFAP-Positive Reactive Astrocyte Subtype Delineation+2 more
A Study Of Oral PF-01913539 In Patients With Mild To Moderate Alzheimer's Disease
NCT01066481 Phase II Withdrawn
Pfizer 2010-04 → 2012-03
The purpose of this study is to demonstrate the safety and efficacy of PF-01913539 in the treatment of patients with mild-to-moderate Alzheimer's Disease. It is a 6-month study enrolling 651 patients
Alzheimer's DiseaseDementiaDimebonPF-01913539 5 mgPF-01913539 5 mgPlacebo
5
hypotheses
HSP90-Tau Disaggregation Complex EnhancementAPOE Isoform Expression Across Glial SubtypesGFAP-Positive Reactive Astrocyte Subtype Delineation+2 more
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild to Moderate Alzheimer's Disease
NCT01689246 Phase III Completed
TauRx Therapeutics Ltd 891 enrolled 2013-01 → 2015-11
The purpose of this study is to determine the safety and efficacy of TRx0237 in the treatment of subjects with mild to moderate Alzheimer's Disease.
Alzheimer's DiseaseTRx0237 150 mg/dayTRx0237 250 mg/dayPlacebo
5
hypotheses
HSP90-Tau Disaggregation Complex EnhancementAPOE Isoform Expression Across Glial SubtypesGFAP-Positive Reactive Astrocyte Subtype Delineation+2 more
Sirtuin-NAD Activator in Alzheimer's Disease
NCT05040321 Phase I Active
Brigham and Women's Hospital
The primary objectives are to: 1. To determine whether MIB-626, after its daily oral administration, penetrates the blood-brain barrier in humans by measuring the cerebrospinal fluid (CSF) concentrat
Alzheimer's Disease (Incl Subtypes)Dementia
5
hypotheses
SIRT1 Activation Couples Mitochondrial Biogenesis to FerroptMetabolic Reprogramming to Reverse SenescencePARP1 Inhibition Therapy+2 more
Safety and Feasibility of Dasatinib and Quercetin in Adults at Risk for Alzheimer's Disease
NCT05422885 Phase I Completed
Lewis Lipsitz 15 enrolled 2022-05-20 → 2024-01-24
AgingDasatinibQuercetin
5
hypotheses
Astrocyte-Microglia Communication Rebalancing via Cytokine MHippocampal-Cortical Transcriptomic Divergence Reveals Accelp16^INK4a-CCF Axis as Senolytic Timing Biomarker+2 more
Peripheral Blood VA/TREM2 Levels and Their Correlation Analysis With the Development and Autistic Symptoms in Children W
NCT06188429 Unknown Unknown
Hua Wei 50 enrolled 2023-11-20 → 2024-03-31
Autism Spectrum Disorder (ASD) is a neurodevelopmental disorder characterized by social impairment, repetitive behaviors, and narrow interests. With advancements in diagnostic techniques, the prevalen
ASDDSM-5
5
hypotheses
TREM2-mediated microglial tau clearance enhancementTREM2-Mediated Microglial Dysfunction Disrupts Perivascular TREM2-Regulated Astrocytic Calcium Dynamics Control Glymphat+2 more
Safety Study of AADvac1, a Tau Peptide-KLH-Conjugate Active Vaccine to Treat Alzheimer's Disease
NCT01850238 Phase I Completed
Axon Neuroscience SE
Alzheimer DiseaseAADvac1Placebo
5
hypotheses
A tau PTM barcode gates trans-synaptic templatingTau/MAP6 ratio as a master switch for microtubule dynamics pRepeat-domain exposure defines seed-competent tau conformers+2 more
Genetic Studies of Early-onset Dementia
NCT04906863 Unknown Recruiting
Columbia University
Dementia, Early OnsetBlood drawNeurocognitive testingMedical questionnaire
5
hypotheses
A tau PTM barcode gates trans-synaptic templatingTau/MAP6 ratio as a master switch for microtubule dynamics pRepeat-domain exposure defines seed-competent tau conformers+2 more
Repurposing Bromocriptine for Abeta Metabolism in Alzheimer's Disease
NCT04413344 Phase I Completed
Kyoto University
Familial Alzheimer Disease (FAD)PSEN1 MutationBromocriptine MesilatePlacebos
5
hypotheses
A tau PTM barcode gates trans-synaptic templatingTau/MAP6 ratio as a master switch for microtubule dynamics pRepeat-domain exposure defines seed-competent tau conformers+2 more
Prevention of Cognitive Decline in ApoE4 Carriers With Subjective Cognitive Decline After EGCG and a Multimodal Interven
NCT03978052 N/A Completed
Parc de Salut Mar
Alzheimer DiseaseCognitive DeclineEGCGPlacebo EGCGHealthy lifestyle recommendations
5
hypotheses
A tau PTM barcode gates trans-synaptic templatingTau/MAP6 ratio as a master switch for microtubule dynamics pRepeat-domain exposure defines seed-competent tau conformers+2 more
Digital Evaluations and Technologies Enabling Clinical Translation for AD
NCT05385913 N/A Unknown
Oregon Health and Science University 200 enrolled 2022-04-01 → 2024-06-30
The DETECT-AD study (stands for "Digital Evaluations and Technologies Enabling Clinical Translation for Alzheimer's Disease") is a new study designed to improve clinical trials for early Alzheimer's d
Alzheimer Disease, Early OnsetMultivitamin-no intervention
5
hypotheses
Targeted APOE4-to-APOE3 Base Editing TherapyCompetitive APOE4 Domain Stabilization PeptidesAPOE4 Allosteric Rescue via Small Molecule Chaperones+2 more
Circadian Rhythm and Other Factors in Memory Clinic Patients
NCT05977712 N/A Recruiting
Assistance Publique - Hôpitaux de Paris 1,200 enrolled 2024-03-06 → 2027-03
The CIRCAME study is a bicentric study of patients from 2 memory clinics in Paris. The main objective is to identify circadian rhythm components and other individual risk factors (sociodemographic, be
DementiaQuestionnaireClinical examinationAccelerometer port
5
hypotheses
Targeted APOE4-to-APOE3 Base Editing TherapyCompetitive APOE4 Domain Stabilization PeptidesAPOE4 Allosteric Rescue via Small Molecule Chaperones+2 more
Retinal Neurodegeneration in Type 2 Diabetes as Biomarker for Alzheimer´s Disease
NCT02360527 N/A Completed
Hospital Universitari Vall d'Hebron Research Insti 126 enrolled 2014-09 → 2015-11
A clear association between type 2 diabetes (T2D) and Alzheimer's disease (AD) has been reported. This association is independent of vascular impairment, and therefore, it could be attributed to neuro
Retinal NeurodegenerationAlzheimer´s DiseaseType 2 Diabetes
5
hypotheses
Targeted APOE4-to-APOE3 Base Editing TherapyCompetitive APOE4 Domain Stabilization PeptidesAPOE4 Allosteric Rescue via Small Molecule Chaperones+2 more
Cognitive Functioning and Quality of Life in CNS Lymphoma
NCT00581737 N/A Completed
Memorial Sloan Kettering Cancer Center 50 enrolled 2000-07 → 2009-08
The purpose of this study is to evaluate several aspects of thinking abilities including attention and memory, and quality of life in patients who were diagnosed with and treated for Primary CNS Lymph
LymphomaCentral Nervous System Lymphoma
5
hypotheses
Targeted APOE4-to-APOE3 Base Editing TherapyCompetitive APOE4 Domain Stabilization PeptidesAPOE4 Allosteric Rescue via Small Molecule Chaperones+2 more
Effect of the Plantago Ovata Husk on the Lipid Profile of Patients With Hypercholesterolemia
NCT00502047 Phase II Completed
Rottapharm Spain 255 enrolled Started 2005-09
The hypothesis of this study is that soluble fibre may contribute to a reduction of the low density lipoprotein cholesterol (LDL-c), and the combined effect with a statin may achieve an optimisation o
HypercholesterolemiaCardiovascular DiseasePlantago ovata husk
5
hypotheses
Targeted APOE4-to-APOE3 Base Editing TherapyCompetitive APOE4 Domain Stabilization PeptidesAPOE4 Allosteric Rescue via Small Molecule Chaperones+2 more
EAGLE: Evaluating Genotypes Using Intravitreal Aflibercept Injection
NCT02689518 Phase IV Completed
University of California, San Diego 50 enrolled 2014-04 → 2019-11-12
Clinical and genetic evaluation of individuals treated with intravitreal aflibercept injection (Eylea) for neovascular age-related macular degeneration (wet AMD)
Macular DegenerationWet Macular DegenerationIntravitreal aflibercept injection
5
hypotheses
Targeted APOE4-to-APOE3 Base Editing TherapyCompetitive APOE4 Domain Stabilization PeptidesAPOE4 Allosteric Rescue via Small Molecule Chaperones+2 more
LIFE-DSR-Biomarker Sub-study of Biomarkers in Down Syndrome Related Alzheimer's Disease (DS-AD)
NCT06860373 Phase III Terminated
LuMind IDSC Foundation
This is an optional sub-study that will enroll participants from the LIFE-DSR parent protocol. Participants will undergo assessments at two timepoints, including: additional blood samples for PBMC and
Down Syndrome
5
hypotheses
TREM2-Mediated Microglial Dysfunction Disrupts Perivascular TREM2-Regulated Astrocytic Calcium Dynamics Control GlymphatTREM2-Mediated Microglial Dysfunction Impairs Synaptic Tau P+2 more
Understanding Alpha-Synuclein Spread in Parkinson's Disease Through Blood Biomarkers and Neuroimaging
NCT07474779 N/A Not Yet Recruiting
University of Pavia
Parkinson's Disease (PD)GBA1 Parkinson DiseaseREM Sleep Behavior Disorder (iRBD)brain imagingblood drawSkin biopsy
5
hypotheses
Exosomal SNCA Propagation from Lysosome-Compromised Neurons PD-Associated GWAS Variants in CTSO and CTSF Genes Create a SNCA Aggregation Hijacks the Endosomal Sorting Complex Requi+2 more
N-DOSE AD: A Dose Optimization Trial of Nicotinamide Riboside in Alzheimer's Disease
NCT05617508 Phase I Completed
University of Helsinki 40 enrolled 2021-01-01 → 2023-06-30
Nicotinamide riboside (NR) is an NAD+ precursor that boosts neuronal NAD+ levels. PARP1 consumes NAD+ during auto-poly(ADP-ribosyl)ation — elevated NAD+ via NR supplementation maintains metabolic resi
Alzheimer DiseaseNicotinamide Riboside 1000mg dailyPlacebo
5
hypotheses
PARP1 Inhibition TherapyNear-infrared light therapy stimulates COX4-dependent mitochMetabolic NAD+ Salvage Pathway Enhancement Through NAMPT Ove+2 more
Neurodegenerative Alzheimer's Disease and Amyotrophic Lateral Sclerosis (NADALS) Basket Trial
NCT05189106 Phase I Completed
Massachusetts General Hospital 17 enrolled 2022-12-05 → 2025-04-24
This is an open-label, biomarker-driven basket trial of baricitinib in people with subjective cognitive disorder, mild cognitive impairment, Alzheimer's disease (AD), Amyotrophic lateral sclerosis (AL
Amyotrophic Lateral SclerosisAlzheimer DiseaseMild Cognitive ImpairmentBaricitinib
5
hypotheses
Glycine-Rich Domain Competitive InhibitionCross-Seeding Prevention StrategyCryptic Exon Silencing Restoration+2 more
Effect of CT1812 Treatment on Brain Synaptic Density
NCT03493282 Phase I Completed
Cognition Therapeutics 43 enrolled 2018-03-28 → 2020-10-16
Study to Evaluate the Safety and Tolerability of Oral CT1812 in Subjects with Mild to Moderate Alzheimer's Disease.
Alzheimer DiseaseActive Treatment- CT1812 100 mgActive Treatment- CT1812 300 mgPlacebo
4
hypotheses
Synaptic Vesicle Tau Capture InhibitionPrefrontal sensory gating circuit restoration via PV interneHippocampal CA3-CA1 circuit rescue via neurogenesis and syna+1 more
Precision Medicine in the Treatment of Epilepsy
NCT05450822 N/A Recruiting
Gitte Moos Knudsen 550 enrolled 2022-02-18 → 2026-12-31
Primary objectives: The purpose of this study is to identify single and composite biomarkers (from neuroimaging, electrophysiological, and non-imaging biological measures), clinical measures (from co
EpilepsyLevetiracetamLevetiracetam TabletsLamotrigine tablet
4
hypotheses
Synaptic Vesicle Tau Capture InhibitionFocused Ultrasound with Microbubble Contrast Agents for AntiBiorhythmic Interference via Controlled Sleep Oscillations+1 more
Cognition, Age, and RaPamycin Effectiveness - DownregulatIon of thE mTor Pathway
NCT04200911 Early Phase I Completed
The University of Texas Health Science Center at S 10 enrolled 2020-06-01 → 2022-01-13
Cognitive Impairment, MildAlzheimer DiseaseRapamune
4
hypotheses
REDD1-mTOR Axis as the Master Regulator — Preservation Over mTORC1 Reactivation as Autophagy-Senescence Divergence PointTFEB Nuclear Translocation to Reset Lysosomal-Hypoxia Axis+1 more
Deciphering the Effect of Moderate Wine Consumption on Healthy Aging Through Postprandial Extracellular Vesicles.
NCT07361887 N/A Recruiting
University of Seville
This study aims to investigate how moderate wine consumption influences circulating extracellular vesicles (EVs) in healthy adults. EVs are small particles released by cells that carry proteins, lipid
Atherosclerosis Cardiovascular DiseaseObesityMetabolic Syndrome
4
hypotheses
Focused Ultrasound with Microbubble Contrast Agents for AntiPiezoelectric Nanochannel BBB DisruptionTranscranial Magnetic Stimulation-Induced Nanoparticle Deliv+1 more
A Study In Neuromyelitis Optica Spectrum Disorder (NMOSD) With Satralizumab As An Intervention
NCT05269667 Phase IV Terminated
Hoffmann-La Roche 4 enrolled 2022-08-02 → 2023-10-26
Objective of the trial is to describe the efficacy and safety of satralizumab in patients with aquaporin-4 (AQP4) antibody seropositive NMOSD, either treatment naive or inadequate responders to previo
Neuromyelitis Optica Spectrum DisorderNMOSDSatralizumab 120 mg
4
hypotheses
Glymphatic System-Enhanced Antibody Clearance ReversalMagnetosonic-Triggered Transferrin Receptor ClusteringSASP-Driven Aquaporin-4 Dysregulation+1 more
Safety and Feasibility of Exablate Blood-Brain Barrier Disruption for Mild Cognitive Impairment or Mild Alzheimer's Dise
NCT05469009 Early Phase I Active
Ali Rezai
Mild Cognitive ImpairmentAlzheimer Disease 1AducanumabExablate Model 4000 Type 2Lecanemab
4
hypotheses
FUS Mutations Alter Stress Granule Material Properties to CoDual-Domain Antibodies with Engineered Fc-FcRn Affinity ModuEngineered Apolipoprotein E4-Neutralizing Shuttle Peptides+1 more
Study Of Rosiglitazone XR In Subjects With Mild-to-Moderate Alzheimers
NCT00550420 Phase III Terminated
GlaxoSmithKline
Alzheimer's DiseaseRosiglitazone XR
4
hypotheses
Selective Cholinergic Protection via APP Pathway ModulationAstrocyte APOE4-Specific Lipid Metabolism CorrectionAPOE-TREM2 Synergistic Modulation+1 more
Nicotinamide Riboside for Mild Cognitive Impairment
NCT03482167 Phase II Completed
Mild Cognitive ImpairmentNicotinamide Riboside
4
hypotheses
SIRT3-Mediated Mitochondrial Deacetylation Failure with PINKMetabolic NAD+ Salvage Pathway Enhancement Through NAMPT OveChromatin Remodeling-Mediated Nutrient Sensing Restoration+1 more
NMN Supplementation in Healthy Adults
NCT02942888 Phase I Completed
AgingNicotinamide Mononucleotide
4
hypotheses
SIRT3-Mediated Mitochondrial Deacetylation Failure with PINKMetabolic NAD+ Salvage Pathway Enhancement Through NAMPT OveChromatin Remodeling-Mediated Nutrient Sensing Restoration+1 more
MitoQ for Alzheimer's Disease
NCT04430517 Phase II Recruiting
Alzheimer DiseaseMitoQ (Mitoquinone)
4
hypotheses
SIRT3-Mediated Mitochondrial Deacetylation Failure with PINKMetabolic NAD+ Salvage Pathway Enhancement Through NAMPT OveChromatin Remodeling-Mediated Nutrient Sensing Restoration+1 more
Implementation and Evaluation of a Rare Disease Algorithm to Identify Persons at Risk of Gaucher Disease Using Data From
NCT05908656 N/A Completed
Sanofi 13 enrolled 2024-04-02 → 2024-08-26
This is a three-phase study comprising both retrospective and prospective components, as follows: Phase I: Deployment of Rare Disease Algorithm: A diagnostic screening algorithm was developed using
Gaucher DiseaseInvestigational procedure
4
hypotheses
Senescent Cell ASM-Complement Cascade InterventionSelective Neutral Sphingomyelinase-2 Inhibition TherapyNeutral Sphingomyelinase-2 Inhibition for Synaptic Protectio+1 more
Safety, Tolerability, PK, and Efficacy Evaluation of Repeat Ascending Doses of Olipudase Alfa in Pediatric Patients <18
NCT02292654 Phase I Completed
Genzyme, a Sanofi Company 20 enrolled 2015-05-01 → 2019-12-09
Primary Objective: To evaluate the safety and tolerability of olipudase alfa administered intravenously in pediatric participants every 2 weeks for 64 weeks. Secondary Objective: To characterize th
Sphingomyelin LipidosisOlipudase alfa
4
hypotheses
Senescent Cell ASM-Complement Cascade InterventionSelective Neutral Sphingomyelinase-2 Inhibition TherapyNeutral Sphingomyelinase-2 Inhibition for Synaptic Protectio+1 more
Efficacy, Safety, Pharmacodynamic, and Pharmacokinetics Study of Olipudase Alfa in Patients With Acid Sphingomyelinase D
NCT02004691 Phase II Completed
Genzyme, a Sanofi Company 36 enrolled 2015-12-18 → 2021-03-15
Primary Objective: The primary objective of this phase 2/3 study was to evaluate the efficacy of olipudase alfa (recombinant human acid sphingomyelinase) administered intravenously once every 2 weeks
Sphingomyelin Lipidosisplacebo (saline)Olipudase alfa
4
hypotheses
Senescent Cell ASM-Complement Cascade InterventionSelective Neutral Sphingomyelinase-2 Inhibition TherapyNeutral Sphingomyelinase-2 Inhibition for Synaptic Protectio+1 more
Data Analysis of Adult and Pediatric Participants With Acid Sphingomyelinase Deficiency (ASMD) on Early Access to Olipud
NCT05359276 Unknown Completed
Sanofi 40 enrolled 2022-06-10 → 2024-12-31
Primary Objective: To describe the lung, spleen and liver outcomes of olipudase alfa Secondary Objectives: * To describe the patient's characteristics * To describe conditions of olipudase alfa use
Acid Sphingomyelinase Deficiency (ASMD)Olipudase alfa
4
hypotheses
Senescent Cell ASM-Complement Cascade InterventionSelective Neutral Sphingomyelinase-2 Inhibition TherapyNeutral Sphingomyelinase-2 Inhibition for Synaptic Protectio+1 more
Compassionate Use Program for Olipudase Alfa Enzyme Replacement Therapy for Patients With Chronic Acid Sphingomyelinase
NCT04877132 Unknown APPROVED_FOR_MARKETING
Sanofi
The objective of this program is to provide access to enzyme replacement therapy (ERT) with olipudase alfa for certain patients with ASMD, a severe, life threatening disease, that could not participat
Sphingomyelin Lipidosisolipudase alfa (GZ402665)
4
hypotheses
Senescent Cell ASM-Complement Cascade InterventionSelective Neutral Sphingomyelinase-2 Inhibition TherapyNeutral Sphingomyelinase-2 Inhibition for Synaptic Protectio+1 more
Dyslipidemia and Diabetic Retinopathy
NCT03403283 Unknown Completed
University of Alabama at Birmingham 45 enrolled 2014-01 → 2023-04-30
The purpose of this study is to determine if the reparative cells of blood vessels called endothelial progenitor cells(EPC) are defective in people with diabetes.
Diabetic RetinopathyDyslipidemia15 subjects with Non Proliferative DiabeHealthy Controls 15 age matched control
4
hypotheses
Senescent Cell ASM-Complement Cascade InterventionSelective Neutral Sphingomyelinase-2 Inhibition TherapyNeutral Sphingomyelinase-2 Inhibition for Synaptic Protectio+1 more
Non-inferiority Study of Ocrelizumab and Rituximab in Active Multiple Sclerosis
NCT04688788 Phase III Active
Rigshospitalet, Denmark 600 enrolled 2021-04-28 → 2026-05-05
The DanNORMS study is a phase 3, non-inferiority clinical trial examining whether treatment of active multiple sclerosis with rituximab is non-inferior to ocrelizumab regarding efficacy and safety.
Relapsing Remitting Multiple SclerosisSecondary Progressive Multiple SclerosisPrimary Progressive Multiple SclerosisRituximabOcrelizumabFexofenadine
4
hypotheses
Complement C1q Subtype SwitchingComplement C1q Mimetic Decoy TherapyComplement C1QA Spatial Gradient in Cortical Layers+1 more
Amyotrophic Lateral Sclerosis (ALS) Families Project
NCT03865420 N/A Recruiting
Columbia University 300 enrolled 2018-09-11 → 2027-01
This program provides family members of individuals with familial ALS the opportunity to contribute to research focused on learning more about why motor neuron degeneration begins and how or why it pr
ALS
4
hypotheses
Glycine-Rich Domain Competitive InhibitionCross-Seeding Prevention StrategyCryptic Exon Silencing Restoration+1 more
A Nutritional Intervention for Body, Brain, and Longevity Effects (NIBBLE)
NCT06682767 N/A Not Yet Recruiting
Cedars-Sinai Medical Center
Cerebral Blood FlowAPOE 4FMD1 (LNT22-017-1)Dietary Guidance
4
hypotheses
Cardiovascular-Neuroinflammatory Dual TargetingAstrocyte APOE4-Specific Lipid Metabolism CorrectionAPOE-TREM2 Synergistic Modulation+1 more
Long-term Prospective Study of Korean CADASIL Patients
NCT07497867 Unknown Recruiting
Jeju National University Hospital
CADASILCerebral Autosomal Dominant Arteriopatie
3
hypotheses
Alpha-Beta Oscillation Coupling Enhances lncRNA-9969-MediateTheta-Gamma Coupling Modulates lncRNA-9969-Mediated MitochonHypothesis 7: SST-SST1R/Gamma Entrainment-Enhanced Astrocyte
Dapagliflozin In Alzheimer's Disease
NCT03801642 Phase I Completed
Jeff Burns, MD 46 enrolled 2019-01-29 → 2022-07-07
Alzheimer DiseaseDapagliflozinPlacebo
3
hypotheses
REDD1-mTOR Axis as the Master Regulator — Preservation Over mTORC1 Reactivation as Autophagy-Senescence Divergence PointTFEB Nuclear Translocation to Reset Lysosomal-Hypoxia Axis
TRIAD - Tracking Risk in Integrated Alzheimer's Diagnostics.
NCT07399418 N/A Recruiting
Istituti Clinici Scientifici Maugeri SpA 80 enrolled 2025-09-01 → 2027-07-31
The study is based on the hypothesis that the integration of biological, psychological, and social factors, according to the biopsychosocial paradigm, allows for more accurate identification of the di
Cognitive Decline
3
hypotheses
Circadian Clock-Autophagy SynchronizationGFAP-Positive Reactive Astrocyte Subtype DelineationTemporal Decoupling via Circadian Clock Reset
A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Di
NCT02565511 Phase II Terminated
Novartis Pharmaceuticals
Alzheimers DiseaseCAD106 ImmunotherapyPlacebo to CAD106CNP520
3
hypotheses
Vicious Cycle Hypothesis: Cholinergic Dysfunction ExacerbateGlymphatic-Mediated Tau Clearance DysfunctionPalmitoylation-Targeted BACE1 Trafficking Disruptors
CERebrolysine Effect on Blood-brain Barrier in acUte Ischemic Stroke
NCT06078215 Phase IV Unknown
Poznan University of Medical Sciences
The study investigates whether Cerebrolysin stabilizes blood-brain barrier integrity in a manner that can be monitored using serum levels of the principal tight junction proteins, e.g., occludin (OCL)
Acute Ischemic Stroke
3
hypotheses
Focused Ultrasound with Microbubble Contrast Agents for AntiPiezoelectric Nanochannel BBB DisruptionTranscranial Magnetic Stimulation-Induced Nanoparticle Deliv
The Cognitive-Behavioral Dysfunctions and the Potential of Neuroplasticity in Brain Tumors Patients During Radiotherapy
NCT05192447 N/A Unknown
The Greater Poland Cancer Centre
Primary and secondary brain tumors are a constant challenge for the medicine. Tissue sensitivity to ionizing radiation differs and depends on numerous factors and the same dose of radiation may produc
Brain TumorsRadiotherapy
3
hypotheses
Focused Ultrasound with Microbubble Contrast Agents for AntiPiezoelectric Nanochannel BBB DisruptionTranscranial Magnetic Stimulation-Induced Nanoparticle Deliv
Non-invasive Blood-brain Barrier Opening in Alzheimer's Disease Patients Using Focused Ultrasound
NCT04118764 N/A Completed
Columbia University
Alzheimer DiseaseNeuronavigation-guided single-element foDefinityMagnetic Resonance Imaging (MRI) with or
3
hypotheses
FUS Mutations Alter Stress Granule Material Properties to CoGap Junction Hemichannel Modulation for Controlled MitochondASO-Mediated Exon Skipping to Restore FUS-TAZ Chaperone Axis
Early Diagnosis of SCD Based on Radiogenomics
NCT04696315 Unknown Unknown
XuanwuH 2
Alzheimer DiseaseSubjective Cognitive DeclineNeuroimagingMultiple features extraction
3
hypotheses
Peripheral-Central Immune Decoupling TherapyTREM2-APOE4 Co-targeting — Simultaneous Correction of Lipid Cell-Type Specific TREM2 Upregulation in DAM Microglia
The Role of Muscle Protein Breakdown in the Regulation of Muscle Quality in Frail Elderly Individuals
NCT03326648 N/A Completed
Truls Raastad 34 enrolled 2016-09-01 → 2017-12-20
The purpose of this study is to investigate mechanisms underlying the reduction in muscle quality (the ratio between muscle strength and muscle size) with aging, and to investigate how these factors a
SarcopeniaStrength trainingProtein supplementation
3
hypotheses
TFEB-PGC1α Mitochondrial-Lysosomal DecouplingFOXO3-Longevity Pathway Epigenetic ReprogrammingThe Mitochondrial-Lysosomal Metabolic Coupling Dysfunction
Trial for Relapsed or Refractory AML Patients Combining Cytarabine and Mitoxantrone With Venetoclax (RELAX)
NCT04330820 Phase I Unknown
Technische Universität Dresden 55 enrolled 2020-04-06 → 2023-10-11
This is an open-label Phase I dose-escalation study of oral venetoclax in combination with increasing cytarabine doses plus mitoxantrone to define the safety profile and MTD of cytarabine in subjects
Relapsed Adult AMLRefractory AMLVenetoclax Oral Tablet
3
hypotheses
Pericyte Contractility Reset via Selective PDGFR-β AgonismEpigenetic Memory Erasure via TET2 ActivationTET2-Mediated Demethylation Rejuvenation Therapy
Omics of Rituximab-resistance
NCT07416942 N/A Not Yet Recruiting
Mario Negri Institute for Pharmacological Research 120 enrolled 2026-04 → 2029-03
The CONFUCIUS project aims to establish a personalised medicine framework for MN patients by integrating pharmacogenomics with other -omics technologies in order to identify biomarkers that predict re
Membranous NephropathyMulti-omics AnalysisSample collection
3
hypotheses
Complement C1q Subtype SwitchingComplement C1q Mimetic Decoy TherapyComplement C1QA Spatial Gradient in Cortical Layers
The Effectivity of Anti Tuberculosis Therapy in Idiopathic Uveitis with Positive IGRA
NCT05005637 Phase II Completed
Fakultas Kedokteran Universitas Indonesia 78 enrolled 2021-08-27 → 2024-10-20
The reported incidence of uveitis is 52 persons per year per 100,000 population, with a greater incidence estimated in developing countries, including Indonesia. Uveitis has challenges in diagnosis an
Tuberculous UveitisAnti Tuberculosis DrugMethylprednisolone
3
hypotheses
Complement C1q Subtype SwitchingComplement C1q Mimetic Decoy TherapyComplement C1QA Spatial Gradient in Cortical Layers
Mobilising Tumour and Immune Cells Via Exercise in Chronic Lymphocytic Leukaemia
NCT05093192 N/A Completed
University of Bath 26 enrolled 2021-10-01 → 2022-12-06
Chronic lymphocytic leukaemia (CLL) is the most common adult blood cancer in the United Kingdom. CLL means that many cancer cells appear in the blood, bone marrow and other tissues, for example, the s
Chronic Lymphocytic LeukemiaMinimal Residual DiseaseExercise trial
3
hypotheses
Complement C1q Subtype SwitchingComplement C1q Mimetic Decoy TherapyComplement C1QA Spatial Gradient in Cortical Layers
Combined Apheresis for ABO-incompatible Transplantation - a Pilot Study
NCT02120482 N/A Terminated
Medical University of Vienna 4 enrolled 2014-10 → 2022-07-31
Recipient desensitization is a prerequisite for successful ABO-incompatible kidney transplantation (ABOi-KTX). Published desensitization protocols commonly include the use of plasmapheresis or selecti
Decreased Immunologic ActivityAntibody-mediated RejectionCombined apheresis
3
hypotheses
Complement C1q Subtype SwitchingComplement C1q Mimetic Decoy TherapyComplement C1QA Spatial Gradient in Cortical Layers
Personalized Antisense Oligonucleotide Therapy for A Single Participant With TARDBP ALS
NCT07095712 Phase I Active
n-Lorem Foundation 1 enrolled 2024-11-25 → 2025-11
This research project entails delivery of a personalized antisense oligonucleotide (ASO) drug designed for a single participant with amyotrophic lateral sclerosis (ALS) due to a pathogenic variant in
Amyotrophic Lateral SclerosisnL-TARD-001
3
hypotheses
Glycine-Rich Domain Competitive InhibitionCross-Seeding Prevention StrategyCryptic Exon Silencing Restoration
Amyotrophic Lateral Sclerosis Registry in Thailand
NCT07175935 N/A Recruiting
Chulalongkorn University 100 enrolled 2025-03-01 → 2030-12-31
This is a prospective, observational, multicenter registry designed to collect comprehensive clinical, genetic, and outcome data from patients diagnosed with amyotrophic lateral sclerosis (ALS) across
ALS (Amyotrophic Lateral Sclerosis)
3
hypotheses
Glycine-Rich Domain Competitive InhibitionCross-Seeding Prevention StrategyCryptic Exon Silencing Restoration
Clinical Characteristics, Natural History, Health Care Measures, and Genetic Screening in Patients With ALS
NCT05852405 N/A Completed
Ambulanzpartner Soziotechnologie APST GmbH 2,000 enrolled 2021-08-01 → 2024-12-31
Patients with sporadic ALS (sALS), which refers to those without a family history of ALS, are typically not subjected to genetic investigations as part of their standard care. Therefore, their mutatio
Motor Neuron Disease, Amyotrophic Latera
3
hypotheses
Glycine-Rich Domain Competitive InhibitionCross-Seeding Prevention StrategyCryptic Exon Silencing Restoration
Cilostazol in Parkinson&#39;s Disease
NCT06612593 Phase II Not Yet Recruiting
Ain Shams University 50 enrolled 2024-10-01 → 2025-10-01
Parkinson's disease is the second most common neurodegenerative diseases. The conventional treatment for PD has included dopaminergic treatment as Levodopa\\carbidopa or dopamine agonists, anti-cholin
Parkinson's DiseaseCilostazolPlaceboStandard treatment
3
hypotheses
IL-10-Producing B10 Cells Establish AQP4-Specific PeripheralTLR4/MyD88/NF-κB Axis Blockade to Interrupt LPS-Mediated GutAryl Hydrocarbon Receptor (AHR) Activation in B Cells Determ
Adapting Connect-Home Transitional Care for the Unique Needs of Persons With Alzheimer's Disease and Other Dementias and
NCT05887388 N/A Completed
University of North Carolina, Chapel Hill 38 enrolled 2021-09-10 → 2022-02-27
This primary purpose of this study will be to (1) examine the feasibility and acceptability of transitional care focusing on care needs of skilled nursing facility (SNF) patients with dementia and the
Pathologic ProcessesConnect-Home Plus
3
hypotheses
Prefrontal sensory gating circuit restoration via PV interneHippocampal CA3-CA1 circuit rescue via neurogenesis and synaHippocampal CA3-CA1 synaptic rescue via DHHC2-mediated PSD95
Effects of Electroacupuncture on Cognitive Symptoms in Major Depressive Disorder
NCT06239740 N/A Completed
Thammasat University 60 enrolled 2022-12-24 → 2023-01-24
The goal of this pilot Study and Randomized Controlled Trial is to investigate the impact of electroacupuncture on cognitive function, quality of life (QoL), and depression severity in patients with m
Major Depressive DisordersCognitive DysfunctionElectroacupuncture groupSham acupuncture
3
hypotheses
Prefrontal sensory gating circuit restoration via PV interneHippocampal CA3-CA1 circuit rescue via neurogenesis and synaHippocampal CA3-CA1 synaptic rescue via DHHC2-mediated PSD95
Dopaminergic Enhancement of Learning and Memory in Healthy Adults and Patients With Dementia/Mild Cognitive Impairment
NCT00306124 Phase IV Unknown
University Hospital Muenster 120 enrolled Started 2006-01
This study aims to determine whether levodopa is effective in boosting learning and memory in healthy subjects and patients with dementia or Mild Cognitive Impairment. We also examine in healthy subj
Alzheimer's DiseaseMild Cognitive ImpairmentHealthyLevodopa
3
hypotheses
Prefrontal sensory gating circuit restoration via PV interneHippocampal CA3-CA1 circuit rescue via neurogenesis and synaHippocampal CA3-CA1 synaptic rescue via DHHC2-mediated PSD95
Deep Transcranial Magnetic Stimulation in Patients With Alzheimer's Disease
NCT00753662 Phase II Unknown
Tel-Aviv Sourasky Medical Center 45 enrolled 2008-11 → 2012-11
The primary objective of this trial is to assess the ability of Transcranial Magnetic Stimulation with H2 coil to prefrontal and parieto-temporal cortex to improve cognitive performance in patients wi
Alzheimer's Disease1Hz TMS with H2 coil10Hz TMS with H2 coil to prefrontal and SHAM TMS with H2 coil
3
hypotheses
Prefrontal sensory gating circuit restoration via PV interneHippocampal CA3-CA1 circuit rescue via neurogenesis and synaHippocampal CA3-CA1 synaptic rescue via DHHC2-mediated PSD95
Impact of a Multimodal Lifestyle Intervention on Dementia Risk Factors and Attitude Related to Dementia Risk: A Logistic
NCT07146412 N/A Recruiting
HudsonAlpha Institute for Biotechnology
Cognitive ImpairmentAlzheimer Blood BiomarkersAlzheimer Disease (AD)Multimodal Lifestyle Intervention
3
hypotheses
Astrocyte APOE4-Specific Lipid Metabolism CorrectionAPOE-TREM2 Synergistic ModulationAPOE4-Lipid Metabolism Correction
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
NCT01741194 Phase II Completed
Cerecin
Alzheimer's DiseaseAC-1204Placebo
3
hypotheses
Astrocyte APOE4-Specific Lipid Metabolism CorrectionAPOE-TREM2 Synergistic ModulationAPOE4-Lipid Metabolism Correction
Phase II Study Investigating the Combination of Encorafenib and Binimetinib in BRAF V600E Mutated Chinese Patients With
NCT05195632 Phase II Active
Pierre Fabre Medicament
This is a phase 2, multicenter, single-arm study with a safety lead-in to investigate the efficacy, safety and pharmacokinetics of encorafenib 450 mg once daily (QD) in combination with binimetinib 45
Non-Small Cell Lung Cancer
3
hypotheses
Theta-Gamma Cross-Frequency Coupling Modulates lncRNA-9969 PGamma Oscillation Entrainment Enhances lncRNA-9969-Mediated Theta-Alpha Oscillation Entrainment Enhances lncRNA-9969-Med
Efficacy of Add-on Plasma Exchange As an Adjunctive Strategy Against Septic Shock
NCT05726825 N/A Recruiting
Hannover Medical School
Randomized, prospective, multicenter, open-label, controlled, parallel-group interventional trial to test the adjunctive effect of therapeutic plasma exchange in patients with early septic shock.
Septic Shock
3
hypotheses
Theta-Gamma Cross-Frequency Coupling Modulates lncRNA-9969 PGamma Oscillation Entrainment Enhances lncRNA-9969-Mediated Theta-Alpha Oscillation Entrainment Enhances lncRNA-9969-Med
Effects of Pea Proteins on Muscle Damage and Recovery
NCT05657314 N/A Completed
The Center for Applied Health Sciences, LLC
This study is a double-blind, randomized, placebo-controlled, crossover clinical trial of N=40 recreationally active men to be recruited a single investigational center in Ohio (i.e., The Center for A
Pea ProteinsMuscle DamageAmino Acid Change
3
hypotheses
Theta-Gamma Cross-Frequency Coupling Modulates lncRNA-9969 PGamma Oscillation Entrainment Enhances lncRNA-9969-Mediated Theta-Alpha Oscillation Entrainment Enhances lncRNA-9969-Med
Myotonic Dystrophy Type 1 and Resistance Exercise
NCT05036447 N/A Completed
Norwegian School of Sport Sciences
The purpose of this study is to investigate the response after one bout of moderate-heavy resistance exercise in patients suffering from Myotonic Dystrophy type 1. There is still doubt about if these
Myotonic Dystrophy 1
3
hypotheses
Theta-Gamma Cross-Frequency Coupling Modulates lncRNA-9969 PGamma Oscillation Entrainment Enhances lncRNA-9969-Mediated Theta-Alpha Oscillation Entrainment Enhances lncRNA-9969-Med
During-exercise Physiological Effects of Nasal High-flow in Patients With Chronic Obstructive Pulmonary Disease
NCT04014868 N/A Completed
ADIR Association
Chronic obstructive pulmonary disease is a major cause of disability and mortality worldwide. This disease progressively leads to dyspnea and exercise capacity impairment. Pulmonary rehabilitation tea
Chronic Obstructive Pulmonary Disease
3
hypotheses
Theta-Gamma Cross-Frequency Coupling Modulates lncRNA-9969 PGamma Oscillation Entrainment Enhances lncRNA-9969-Mediated Theta-Alpha Oscillation Entrainment Enhances lncRNA-9969-Med
Autoimmune Dementia: Predictors of Neuronal Synaptic Antibodies in Patients With New-ONset Cognitive Impairment
NCT06321588 N/A Recruiting
Azienda Usl di Bologna 300 enrolled 2023-05-10 → 2026-06-30
The goal of this observational study is to investigate the frequency and the possible pathogenic role of neuronal synaptic antibodies (NSAb) in patients with cognitive impairment (CI). The main questi
Cognitive ImpairmentDementia
3
hypotheses
Glymphatic-Mediated Tau Clearance DysfunctionWhite Matter Oligodendrocyte Protection via CXCL10 InhibitioOptimized Temporal Window for Metabolic Boosting Therapy Det
Ambroxol in New and Early DLB, A Phase IIa Multicentre Randomized Controlled Double Blind Clinical Trial
NCT04588285 Phase II Unknown
Helse Fonna
Dementia With Lewy BodiesAmbroxolPlacebo
3
hypotheses
PD-Associated GWAS Variants in CTSO and CTSF Genes Create a GBA1-Deficiency Disrupts Mitochondrial- Lysosomal Contact SiGlucosylceramide Accumulation from GCase Deficiency Disrupts
Prevent Cognitive Decline in GBA-associated Parkinson's Disease
NCT07055087 Phase II Not Yet Recruiting
University Hospital Tuebingen
Parkinson's DiseasePrasinezumabSodium Chloride
3
hypotheses
PD-Associated GWAS Variants in CTSO and CTSF Genes Create a GBA1-Deficiency Disrupts Mitochondrial- Lysosomal Contact SiGlucosylceramide Accumulation from GCase Deficiency Disrupts
Ioflupane I123 (DaTSCAN) and Positron Emission Tomography-computed Tomography Fludeoxyglucose (PET-CT FDG) to Assess Bra
NCT01089283 Unknown Unknown
Tel-Aviv Sourasky Medical Center
Parkinson Disease
3
hypotheses
PD-Associated GWAS Variants in CTSO and CTSF Genes Create a GBA1-Deficiency Disrupts Mitochondrial- Lysosomal Contact SiGlucosylceramide Accumulation from GCase Deficiency Disrupts
Drug Discovery for Parkinson's With Mutations in the GBA Gene
NCT05536388 Unknown Recruiting
New York Stem Cell Foundation Research Institute
Parkinson DiseaseGaucher DiseaseHealthyBiological Sample Collection
3
hypotheses
PD-Associated GWAS Variants in CTSO and CTSF Genes Create a GBA1-Deficiency Disrupts Mitochondrial- Lysosomal Contact SiGlucosylceramide Accumulation from GCase Deficiency Disrupts
Detecting Early Myocardial Infiltration w/Amyloid & Light Chain Deposition Disease in Multiple Myeloma Subjects
NCT01018927 N/A Terminated
University of Arkansas 44 enrolled 2009-06 → 2017-05-30
The purpose of this study is to see if MRI techniques can be used for early evaluation of cardiac amyloidosis which is sometimes seen in individuals with multiple myeloma. Cardiac amyloidosis is a med
Multiple MyelomaAdministering three additional MRI image
3
hypotheses
Dual-Receptor Antibody ShuttlingAPOE4-Specific Proteolytic Fragment Inhibition TherapyAPOE4-Targeted Ultrasonic Lipidation Enhancement for Gamma O
Post-stroke Cognitive Impairment and Dementia
NCT01339195 N/A Completed
Centre Hospitalier Universitaire, Amiens 1,635 enrolled 2010-08 → 2016-12
Projections from epidemiological studies suggest that, among the Western adult population, one in three will present a cerebrovascular accident (stroke), severe cognitive disorders, or both. To better
StrokeCognitive DisordersBehavioral DisordersFrench adaptation of NINDS-Canadian Stro
3
hypotheses
Dual-Receptor Antibody ShuttlingAPOE4-Specific Proteolytic Fragment Inhibition TherapyAPOE4-Targeted Ultrasonic Lipidation Enhancement for Gamma O
A Study Investigating the Effectiveness of a LifeSeasons NeuroQ Supplement With Lifestyle Changes to Improve Cognitive F
NCT04149639 N/A Completed
LifeSeasons Inc. 40 enrolled 2019-11-08 → 2020-07-07
The objective of this study is to evaluate the efficacy of a NeuroQ supplement designed by Dr. Bredesen to complement his Lifestyle modification protocol. Eligible participants will be expected to con
HealthyNeuroQ
3
hypotheses
Dual-Receptor Antibody ShuttlingAPOE4-Specific Proteolytic Fragment Inhibition TherapyAPOE4-Targeted Ultrasonic Lipidation Enhancement for Gamma O
Improving Caregiver Mediated Medication Management- The 3M Study
NCT03127930 N/A Completed
University of Pittsburgh 183 enrolled 2010-06-01 → 2013-07-30
This study sought to improve medication management by caregivers of community dwelling patients with dementia or simple memory loss. This was done by testing a tailored intervention delivered both in-
Medication ManagementIntervention
3
hypotheses
Dual-Receptor Antibody ShuttlingAPOE4-Specific Proteolytic Fragment Inhibition TherapyAPOE4-Targeted Ultrasonic Lipidation Enhancement for Gamma O
Improving Mood and Behavior in Assisted Living Residents Through Skills Training for Their Caregivers
NCT00255866 Phase II Completed
University of Washington 90 enrolled 2004-01 → 2006-12
This study will develop a treatment program to reduce mood and behavior problems in assisted living residents who have dementia.
DementiaAlzheimer DiseaseSkills training for the care of dementia
3
hypotheses
Dual-Receptor Antibody ShuttlingAPOE4-Specific Proteolytic Fragment Inhibition TherapyAPOE4-Targeted Ultrasonic Lipidation Enhancement for Gamma O
Comfortage - AD Prevention Strategies
NCT06896201 N/A Not Yet Recruiting
Fondazione Policlinico Universitario Agostino Geme 200 enrolled 2025-09 → 2027-03
Study is Interventional, cross-sectional, clinical trial without drug and without device
Alzheimer DiseaseSubjective Cognitive ImpairmentMild Cognitive ImpairmentNeuropsychological Assessments and OtherBlood Exams, Fluid Biomarkers, GeneticsConnectivity Analysis
3
hypotheses
Prime Editing Precision Correction of APOE4 to APOE3 in MicrAPOE4-Specific Proteolytic Fragment Inhibition TherapyAPOE4-Targeted Ultrasonic Lipidation Enhancement for Gamma O
Study Evaluating the Safety and Efficacy of Bapineuzumab in Alzheimer Disease Patients
NCT00676143 Phase III Terminated
Pfizer 1,100 enrolled 2008-01 → 2012-10
This is a study to evaluate the efficacy and safety of multiple doses of bapineuzumab in patients with mild to moderate Alzheimer Disease. Patients will receive either bapineuzumab or placebo. Each pa
Alzheimer Diseasebapineuzumabplacebo
3
hypotheses
Prime Editing Precision Correction of APOE4 to APOE3 in MicrAPOE4-Specific Proteolytic Fragment Inhibition TherapyAPOE4-Targeted Ultrasonic Lipidation Enhancement for Gamma O
Cognitive Function in Obstructive Sleep Apnea
NCT07364318 N/A Recruiting
Comenius University 30 enrolled 2024-11-01 → 2027-08-31
Obstructive sleep apnea (OSA) is the most common sleep-related breathing disorder and has been increasingly recognized as a contributor to cognitive decline and a potential risk factor for neurodegene
OSA - Obstructive Sleep ApneaCognitive Functions
3
hypotheses
Prime Editing Precision Correction of APOE4 to APOE3 in MicrAPOE4-Specific Proteolytic Fragment Inhibition TherapyAPOE4-Targeted Ultrasonic Lipidation Enhancement for Gamma O
The Swedish BioFINDER Study
NCT01208675 N/A Completed
Skane University Hospital 1,150 enrolled 2010-09 → 2024-12
The present study aims at combining biochemical methods with various types of imaging techniques to identify the pathophysiology of Alzheimer's disease (AD). The main interest is to find markers assoc
Mild Cognitive ImpairmentAlzheimer's DiseaseDementia With Lewy Bodies
3
hypotheses
Prime Editing Precision Correction of APOE4 to APOE3 in MicrAPOE4-Specific Proteolytic Fragment Inhibition TherapyAPOE4-Targeted Ultrasonic Lipidation Enhancement for Gamma O
Detection of Disease-Related Changes in Pre-Symptomatic Alzheimer's Disease
NCT01841905 N/A Unknown
Rhode Island Hospital 60 enrolled 2013-07 → 2016-12
The investigators are conducting a study to try to improve our ability to identify older adults who are at high-risk for progression to Alzheimer's disease, several years before they have symptoms tha
Alzheimer's DiseaseObservational Study
3
hypotheses
Prime Editing Precision Correction of APOE4 to APOE3 in MicrAPOE4-Specific Proteolytic Fragment Inhibition TherapyAPOE4-Targeted Ultrasonic Lipidation Enhancement for Gamma O
Exploring to Remediate Behavioral Disturbances of Spatial Cognition
NCT05944601 N/A Active
Istituto Auxologico Italiano 83 enrolled 2023-03-01 → 2024-02-28
Spatial navigation (SN) has been reported to be one of the first cognitive domains to be affected in Alzheimer's disease (AD), which occurs as a result of progressive neuropathology involving specific
Spatial NavigationVirtual and computer-based cognitive rem
3
hypotheses
Prime Editing Precision Correction of APOE4 to APOE3 in MicrAPOE4-Specific Proteolytic Fragment Inhibition TherapyAPOE4-Targeted Ultrasonic Lipidation Enhancement for Gamma O
Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy For Subjects With Mild To Moderate Alzheimer's Disease
NCT00348309 N/A Completed
GlaxoSmithKline 1,496 enrolled 2006-07-06 → 2009-01-01
Rosiglitazone (RSG) has been tested in clinical studies and is approved by the FDA as a treatment for type II diabetes mellitus, a disease that occurs when the body is unable to effectively use glucos
Alzheimer's DiseaseRosiglitazone Extended Release 2mgRosiglitazone Extended Release 8mgPlacebo
3
hypotheses
Prime Editing Precision Correction of APOE4 to APOE3 in MicrAPOE4-Specific Proteolytic Fragment Inhibition TherapyAPOE4-Targeted Ultrasonic Lipidation Enhancement for Gamma O
Mitochondrial Function Biomarkers in Neurodegeneration
NCT04681943 Observational Recruiting
2
hypotheses
PINK1/Parkin-Independent Mitophagy Bypass for Enhanced DonorGap Junction Hemichannel Modulation for Controlled Mitochond
Longitudinal Study of Ultra-rare Inherited Metabolic and Degenerative Neurological Diseases.
NCT04880356 N/A Recruiting
Fondazione I.R.C.C.S. Istituto Neurologico Carlo B
General aim of the study is the improvement of the clinical knowledge of ultra-rare inherited metabolic and degenerative neurological diseases (prevalence less than 5:100,000) in adulthood through the
Inherited DiseaseRare DiseasesMetabolic Disease
2
hypotheses
TYROBP (DAP12) Conditional Antagonism for Early-Stage NeuropCSF1R-TREM2 Co-Agonism for Sustained Microglial Expansion
Arimoclomol in ALS (ORARIALS-01)
NCT03491462 Phase III Completed
2
hypotheses
Heat Shock Protein 70 Disaggregase AmplificationStress Granule Phase Separation Modulators
Precision Medicine and Neurodegenerative Diseases: Advanced Systems for the Diagnosis and Treatment of Parkinson's Disea
NCT07467460 N/A Recruiting
Neuromed IRCCS 500 enrolled 2026-02-17 → 2028-09-30
In recent decades, advances in medicine have significantly improved both quality of life and life expectancy. However, these positive effects are also associated with a considerable increase in the pr
PARKINSON DISEASE (Disorder)Alzheimer s DiseaseDiabete Type 2
2
hypotheses
Circadian Clock-Autophagy SynchronizationTemporal Decoupling via Circadian Clock Reset
GLP-1 Analogue in Preventing Progression of Small Vessel Disease (GAPP-SVD)
NCT05356104 Phase II Recruiting
Chinese University of Hong Kong 110 enrolled 2022-05-25 → 2026-05
Cerebral small vessel disease (cSVD), a result of neurovascular cell dysfunction, is a major cause of stroke, dementia and mobility problems worldwide. Vascular risk factor control alone may not be su
Cerebral Small Vessel DiseaseExenatide extended release
2
hypotheses
Circadian Clock-Autophagy SynchronizationTemporal Decoupling via Circadian Clock Reset
Transcranial Alternating Current Stimulation in Lewy Body Dementia
NCT07375771 N/A Recruiting
IRCCS Centro San Giovanni di Dio Fatebenefratelli 40 enrolled 2025-10-01 → 2027-09
The aim of the study is to evaluate the safety, feasibility, clinical and biological efficacy, and predictors of efficacy of an intervention consisting of transcranial alternating current stimulation
Lewy Body Dementia (LBD)Transcranial Alternating Current StimulaTranscranial Alternating Current StimulaSham Transcranial Alternating Current St
2
hypotheses
Circadian Clock-Autophagy SynchronizationTemporal Decoupling via Circadian Clock Reset
WHIte MAtter Hyperintensity Shape and Glymphatics
NCT06010511 N/A Recruiting
Leiden University Medical Center 50 enrolled 2023-01-18 → 2026-08-30
In a society with increased life expectancy, the economic, social and personal burden of dementia increases. Dementia is often caused by a combination of neurovascular and neurodegenerative diseases.
Cerebral Small Vessel DiseasesDementia, MixedDementia, Vascular3T MRI scan7T MRI scanNeuropsychological assessment
2
hypotheses
Circadian Clock-Autophagy SynchronizationTemporal Decoupling via Circadian Clock Reset
Daily Intake of Multivitamin & Mineral Supplementation Effects on Biological Age of Relatively Healthy Middle-aged Indiv
NCT06666660 N/A Recruiting
National University of Singapore 400 enrolled 2024-09-23 → 2025-04-30
Micronutrients, such as vitamins and minerals, are required to sustain fundamental physiological processes in individuals. As individuals age, the risk of having suboptimal levels of micronutrients in
Relatively Healthy VolunteersMultivitamin/Mineral supplementsPlacebo
2
hypotheses
Circadian Clock-Autophagy SynchronizationTemporal Decoupling via Circadian Clock Reset
fNIRS Studies of Music Intervention of Parkinson's Disease
NCT04212897 N/A Unknown
The First Affiliated Hospital of Dalian Medical Un 150 enrolled 2021-01-18 → 2021-12
Functional near-infrared spectroscopy (fNIRS) will be used to monitor neuronal activities and connectivity to elucidate the correlation between physiological changes within the brain and the benefits
Parkinson DiseaseMusic Therapy
2
hypotheses
Circadian Clock-Autophagy SynchronizationTemporal Decoupling via Circadian Clock Reset
Enhancing the Therapeutic Efficacy of Sleep Deprivation by Modafinil
NCT00670813 Phase II Withdrawn
Technical University of Munich 30 enrolled 2008-05 → 2009-11
The study aims to investigate whether the administration of the stimulant modafinil during a 40 hour sleep deprivation period in depressed patients can intensify the antidepressant effect of the sleep
DepressionModafinil (Vigil)Placebo
2
hypotheses
Circadian Clock-Autophagy SynchronizationTemporal Decoupling via Circadian Clock Reset
Frailty Prevention in Elders From Reunion Island
NCT05090241 N/A Completed
Universite de La Reunion 147 enrolled 2021-11-01 → 2023-12-27
In Reunion Island, people encounter environmental and social conditions leading to premature ageing and subsequent frailty. The study evaluates tools, supported by the latest scientific advances in "
Geriatric AssessmentFrail Elderly SyndromePreventionInstrumental measurement of balance and
2
hypotheses
Circadian Clock-Autophagy SynchronizationTemporal Decoupling via Circadian Clock Reset
Daridorexant to Treat Insomnia in Patients With Mild Cognitive Impairment and Mild to Moderate Alzheimer Disease
NCT05924425 Phase IV Recruiting
University Hospital, Montpellier
Alzheimer DiseaseInsomnia DisorderSleepDaridorexant 50 mgPlaceboPolysomnography
2
hypotheses
Night-phase orexin receptor antagonism rescues AD by restoriOrexin-Microglia Modulation Therapy
Daridorexant for Alzheimer Disease Prevention
NCT07213349 Phase II Recruiting
Douglas Mental Health University Institute
Alzheimer Disease (AD)Daridorexant 50 mgPlacebo
2
hypotheses
Night-phase orexin receptor antagonism rescues AD by restoriExcess orexin-A worsens AD cognition through wake-driven amy
Effect of Liraglutide on Clock Genes
NCT02783196 N/A Unknown
Tel Aviv University
This study is undertaken to search whether glucagon-like peptide-1 (GLP-1) analogue, Liraglutide, by enhancing clock gene and AMPK-SIRT-1 mRNA expression, may reverse the metabolic abnormalities of ty
Type 2 Diabetes
2
hypotheses
SIRT1 Activation Couples Mitochondrial Biogenesis to FerroptCircadian Rhythm Entrainment of Reactive Astrocytes
Targeting Neuroinflammation as a Contributing Pathology in Alzheimer's Disease Dementia and Related Dementias
NCT04786223 Phase II Enrolling
Val Lowe 125 enrolled 2021-03-30 → 2028-03
Alzheimer DiseaseLewy Body's DementiaC-11 ER-176Blood Test
2
hypotheses
Astrocyte-Microglia Communication Rebalancing via Cytokine MIL-6 Trans-Signaling Blockade at the Oligodendrocyte-Microgl
Improving Dementia Caregiver Sleep & the Effect on Heart Disease Biomarkers
NCT01550172 N/A Completed
University of South Florida 80 enrolled 2012-04 → 2016-07
Caregivers of Persons With DementiaSleep Behavioral Therapy A and NHMSSleep Behavioral Therapy B and NHMS
2
hypotheses
Astrocyte-Microglia Communication Rebalancing via Cytokine MIL-6 Trans-Signaling Blockade at the Oligodendrocyte-Microgl
Hormone Replacement Trial Against ALzheimers' Disease
NCT04312399 N/A Recruiting
University Hospital, Ghent
Postmenopausal SymptomsAlzheimer Diseaseblood take
2
hypotheses
Vicious Cycle Hypothesis: Cholinergic Dysfunction ExacerbatePalmitoylation-Targeted BACE1 Trafficking Disruptors
A Study of CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease
NCT03131453 Phase II Terminated
Novartis Pharmaceuticals
Alzheimers DiseaseCNP520 50mgCNP520 15mgMatching placebo
2
hypotheses
Vicious Cycle Hypothesis: Cholinergic Dysfunction ExacerbateGlymphatic-Mediated Tau Clearance Dysfunction
Methylene Blue and Postoperative Neurocognitive Disorders
NCT04529265 N/A Completed
Fudan University
Postoperative Neurocognitive Disorders are the most common neurological complications after major surgery, which are associated with higher increased mortality and morbidity in elderly patients underg
Postoperative Delirium
2
hypotheses
Focused Ultrasound with Microbubble Contrast Agents for AntiTranscranial Magnetic Stimulation-Induced Nanoparticle Deliv
Study of LX1001 APOE Gene Therapy in APOE4 Homozygotes
NCT03634007 Phase I Active
15 enrolled Started 2019-01-15
Alzheimer's DiseaseLX1001 (AAV-APOE2 gene therapy)
2
hypotheses
APOE Isoform Expression Across Glial SubtypesEngineered Apolipoprotein E4-Neutralizing Shuttle Peptides
Probiotics in Mild Alzheimer's Disease
NCT06181513 Early Phase I Recruiting
University of Nicosia
Neurodegenerative DiseasesCognition Disorders in Old AgeProbiotic Blend Capsule
2
hypotheses
Blood Monocyte Epigenetic Signature as Surrogate for MicroglIL-6 Trans-Signaling Blockade at the Oligodendrocyte-Microgl
P2X7 Receptor, Inflammation and Neurodegenerative Diseases
NCT03918616 Unknown Completed
University of Pisa
Neuro-Degenerative DiseaseMemantine, Dopamine receptor-agonists
2
hypotheses
Blood Monocyte Epigenetic Signature as Surrogate for MicroglAryl Hydrocarbon Receptor (AhR) Activation by Microbiome Met
Effects of Ozanimod on Immune-mediated Mechanisms of Neurodegeneration in Multiple Sclerosis - a Preclinical Study
NCT05245344 N/A Unknown
Neuromed IRCCS 154 enrolled 2022-04-01 → 2023-06-30
This is a prospective non interventional study including patients with Relapsing-Remitting Multiple Sclerosis (RRMS) or with Neuromyelitis Optica Spectrum Disorders (NMOSD) and healthy subjects, who a
Relapsing-Remitting Multiple Sclerosis (Neuromyelitis OpticaHealthyPeripheral blood withdrawal
2
hypotheses
Glymphatic System-Enhanced Antibody Clearance ReversalSASP-Driven Aquaporin-4 Dysregulation
Frequency of FCGR3A Gene Polymorphisms in Patients With Neuromyelitis Optica Spectrum Disorders, Anti-oligodendrocyte My
NCT06865274 N/A Recruiting
Fondazione Policlinico Universitario Agostino Geme 50 enrolled 2025-02-20 → 2026-02-28
The goal of this study is to assess the frequency of genetic polymorphisms of the FCG3A in a cohort of Italian patients affected by neuromyelitis optica spectrum disorder (NMOSD) and mog antibody asso
Neuromyelitis Optica Spectrum DisordersMOGADMultiple SclerosisBlood draw for the laboratory assessment
2
hypotheses
Glymphatic System-Enhanced Antibody Clearance ReversalSASP-Driven Aquaporin-4 Dysregulation
Clinic Registry Study of Optic Neuromyelitis Spectrum Disease in China
NCT03514030 N/A Unknown
Beijing Tongren Hospital 400 enrolled 2018-04-01 → 2020-04
In 1894, Devic first proposed the concept of neuromyelitis optica(NMO). NMO is an inflammatory demyelinating disease that selectively affects the central nervous system of the optic nerve and spinal c
NMO Spectrum Disorder;Registry Studyserum AQP4-antibody testing method
2
hypotheses
Glymphatic System-Enhanced Antibody Clearance ReversalSASP-Driven Aquaporin-4 Dysregulation
Treatment Response Among Chinese Neuromyelitis Optica Spectrum Disorders
NCT04101058 N/A Unknown
Third Affiliated Hospital, Sun Yat-Sen University 200 enrolled 2019-01-21 → 2020-01-02
Neuromyelitis Optica (NMO)/ Neuromyelitis Optica Spectrum Disorders (NMOSD) is an immune-mediated inflammatory demyelinating disease of the central nervous system mainly involving optic nerve and spin
Neuromyelitis Optica Spectrum Disorders
2
hypotheses
Glymphatic System-Enhanced Antibody Clearance ReversalSASP-Driven Aquaporin-4 Dysregulation
Eculizumab For Acute Attack of Neuromyelitis Optica Spectrum Disorder
NCT06673394 Phase II Withdrawn
Tianjin Medical University General Hospital 2025-09-03 → 2026-06-01
Neuromyelitis optica spectrum disorder (NMOSD) is a relapsing, inflammatory autoimmune disorder of the central nervous system characterized by the pathogenic anti-aquaporin 4 antibody (AQP4-IgG). The
Neuromyelitis Optica Spectrum Disorder AComplement protein C5 inhibitorIVMP
2
hypotheses
Glymphatic System-Enhanced Antibody Clearance ReversalSASP-Driven Aquaporin-4 Dysregulation
Inectolizumab With Steroid Optimization in Newly Treated NMOSD
NCT07159893 N/A Not Yet Recruiting
First Affiliated Hospital of Wenzhou Medical Unive 25 enrolled 2025-09 → 2026-05
Title: Study of Inectolizumab Combined With Steroid Hormone Adjustment Strategies in Treatment-naive Patients With Neuromyelitis Optica Spectrum Disease Objective:This study aims to evaluate the stero
Neuromyelitis OpticaAutoimmune DiseasesDemyelinating Autoimmune Diseases, CNSInebilizumab + Rapid Steroid Tapering grInebilizumab + Standard Steroid Tapering
2
hypotheses
Glymphatic System-Enhanced Antibody Clearance ReversalSASP-Driven Aquaporin-4 Dysregulation
Neuronavigation-guided FUS-induced BBB Opening in Alzheimer's Disease Patients and Its Effects on Brain Amyloid and Tau
NCT06600880 Phase I Not Yet Recruiting
Columbia University
Alzheimer Disease, Early OnsetNeuronavigation-guided single-element foLumasonMagnetic Resonance Imaging (MRI) with or
2
hypotheses
FUS Mutations Alter Stress Granule Material Properties to CoASO-Mediated Exon Skipping to Restore FUS-TAZ Chaperone Axis
ExAblate Blood-Brain Barrier Opening for Treatment of Alzheimer's Disease
NCT03739905 N/A Completed
InSightec
Alzheimer DiseaseBlood Brain Barrier (BBB) Disruption
2
hypotheses
FUS Mutations Alter Stress Granule Material Properties to CoASO-Mediated Exon Skipping to Restore FUS-TAZ Chaperone Axis
Hydroxyzine and Risk of Prolongation of QT Interval
NCT02814981 N/A Unknown
University Hospital, Caen 130 enrolled 2015-11 → 2017-08
On 04/30/2015, ANSM (the National Security Agency of Medicines and Health Products) shared an information for general practicioners, pediatricians, anesthesiologists, dermatologists, geriatricians, ps
HydroxyzineLong QT Syndrome
2
hypotheses
Metabolic Reprogramming via Microglial Glycolysis InhibitionMetabolic Switch Targeting for A1→A2 Repolarization
A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cance
NCT04644770 Phase I Active
Janssen Research & Development, LLC 144 enrolled 2020-11-12 → 2027-01-15
The purpose of this study is to determine the recommended Phase 2 dose(s) (RP2D\[s\]) of JNJ-69086420 in Part 1 (Dose Escalation), to determine safety and preliminary signs of clinical activity at the
Prostatic NeoplasmsAdenocarcinomaJNJ-69086420JNJ-78278343Stereotactic body radiation therapy
2
hypotheses
Metabolic Reprogramming via Microglial Glycolysis InhibitionMetabolic Switch Targeting for A1→A2 Repolarization
A Study of JNJ-78278343 in Combination With JNJ-95298177 for Treatment of Prostate Cancer
NCT07082920 Phase I Recruiting
Janssen Research & Development, LLC 140 enrolled 2025-07-07 → 2027-01-28
The purpose of this study is to identify the recommended phase 2 combination dose (RP2CD) of JNJ-78278343 in combination with JNJ-95298177 in Part 1 (Dose confirmation) of the study and to determine h
Prostatic NeoplasmsJNJ-78278343JNJ-95298177
2
hypotheses
Metabolic Reprogramming via Microglial Glycolysis InhibitionMetabolic Switch Targeting for A1→A2 Repolarization
Non-specific Effects of Vaccination on Mortality and Morbidity
NCT03176719 N/A Unknown
Radboud University Medical Center 1,005 enrolled 2017-06-17 → 2017-10-31
It has long been recognized that the positive effects of vaccination on childhood mortality cannot be solely attributed to a decline in the disease targeted by the vaccine. These so-called non-specifi
Vaccine ReactionAnemiaMalaria,FalciparumVenipuncture
2
hypotheses
Metabolic Reprogramming via Microglial Glycolysis InhibitionMetabolic Switch Targeting for A1→A2 Repolarization